aspirin has been researched along with thiophenes in 308 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 65 (21.10) | 18.7374 |
| 1990's | 7 (2.27) | 18.2507 |
| 2000's | 59 (19.16) | 29.6817 |
| 2010's | 177 (57.47) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Duffy, EM; Jorgensen, WL | 1 |
| Van Nueten, JM | 1 |
| Debelic, M; Radielovic, P; Wuethrich, B | 1 |
| Wüthrich, B | 1 |
| Boneu-Valmalette, A; Bugat, R; Combes, PF; David, JF | 1 |
| Abiko, Y; Ashida, SI | 1 |
| Ferber, RH; Parrish, SL; Vigdahl, RL | 1 |
| Abiko, Y; Ashida, S | 1 |
| Blanchard, JF; Blatrix, CE; Panak, EA; Thebault, JJ | 1 |
| De Clerck, F; Reneman, R; Vermylen, J | 1 |
| Janssen, PA; Niemegeers, CJ; Van Bruggen, JA | 1 |
| Janssen, PA; Niemegeers, CJ | 1 |
| Awouters, F; Janssen, PA; Lenaerts, FM; Niemegeers, CJ | 3 |
| Janssen, PA; Lenaerts, FM; Niemegeers, CJ | 1 |
| Breddin, HK; Fellier, H; Giedrojc, J | 1 |
| Belliardo, F; Bruno, G; La Rosa, C; Lucarelli, C; Pelloso, R | 1 |
| Cowan, A; Wheeler-Aceto, H | 1 |
| Asai, F; Ito, T; Matsuda, K; Oshima, T; Ushiyama, S | 1 |
| Kienast, J; Verstraete, M | 1 |
| Przybilla, B; Ring, J; Ruzicka, T; Schwab-Przybilla, U | 1 |
| Cannizzaro, S; Davì, G; Giubilato, A; Strano, A | 1 |
| Hayashida, N | 1 |
| Harker, LA | 2 |
| Abramowicz, M; Degaute, JP; Leeman, M; Naeije, R; Prost, JF; Reuse, C | 1 |
| Alberca, I; Cattaneo, M; Coccato, MP; Faioni, E; Mannucci, PM; Mari, D; Vianello, L; Vicente, V | 1 |
| Brown, BG; Chesebro, JH; Ekeström, S; Harker, LA; Henderson, AH; Jewitt, DE; Oliver, MF; Sleight, P; Verstraete, M | 1 |
| Hatsuoka, M; Kashii, A; Sasaki, K; Seiki, M | 1 |
| Edgerton, TA; Faust, KB; Geisinger, KR; Hansen, KJ; Howe, HR; Kon, ND; Meredith, JH | 1 |
| Di Perri, T | 1 |
| Díez, M; Fernández, A; Gil, M; Lasierra, J; Velázquez, E; Viladés, E | 1 |
| Hashimoto, N; Kholoussy, AM; Kumashiro, R; Matsumoto, T; Piotrowski, JJ | 1 |
| Bernat, A; Maffrand, JP; Roncucci, R; Vallée, E | 1 |
| Goto, K; Imamura, H; Nakanishi, M | 1 |
| Ikegami, K; Imamura, H; Nakanishi, M | 1 |
| Bennert, C; Berger, E; Jäger, W; Kauschmann, R; Kutschera, J; Pietsch, U; Riese, W; Wendeberg, H | 1 |
| Beller, FK; Slabber, CF; Theiss, W | 1 |
| Iwata, N; Sakai, Y | 1 |
| Czerniawska-Mysik, G; Kuklinski, P; Serwonska, M; Szczeklik, A | 2 |
| Breddin, HK; Pauliks, V; Weichert, W | 1 |
| Offerhaus, L | 1 |
| Tullio, D | 1 |
| Kester, RC | 1 |
| Gaillard, JL; Kher, A; Lecompte, T; Samama, M | 1 |
| Hass, WK; Kamm, B | 1 |
| Tohgi, H | 1 |
| Díez, MM; Fernández, A; Gil, M; Lasierra, J; Velázquez, E; Viladés, E | 1 |
| Butler, KD; White, AM | 1 |
| Naruse, T; Ogawa, S | 1 |
| Pinon, JF | 1 |
| Hanson, SR; Harker, LA | 1 |
| Goyan, JE | 1 |
| Kholoussy, AM; Kumashiro, R; Matsumoto, T; Pavlides, CA | 1 |
| Paris, J | 1 |
| Blanchard, J; Blatrix, C; Panak, E; Thébault, JJ | 1 |
| Bertelé, V; de Gaetano, G | 1 |
| Verstraete, M | 1 |
| Chevolet, C; Dresse, A; Grosdent, JC; Reiters, GM | 1 |
| Conard, J; Horellou, MH; Lecrubier, C; Samama, M | 1 |
| Furukawa, Y; Kondo, M; Murakami, M; Takemura, S; Yoshikawa, T | 1 |
| Donald, JF; Molla, AL | 1 |
| Altmayer, P; Lücker, PW; Marećek, N; Penth, B; Wetzelsberger, K | 1 |
| La Coste, JJ; Milroy, E; Ormiston, MC; Thornton, EJ; Vaughton, KC | 1 |
| Cutting, CJ; Thornton, EJ | 1 |
| Aubert, D; Ferrand, C; Loubrie, JC; Tuong, A; Tuong, CC | 1 |
| Abiko, Y; Ashida, S; Sakuma, K | 1 |
| Lindsay, R; Nunn, B | 1 |
| Conroy, MC; Finkel, M; Grabow, D; Lesch, M; Low, J; Metz, A; Schrier, D; Sommers, C; Wallace, J | 1 |
| Reddy, BS | 1 |
| Danon, A; Rimon, G; Rosenstock, M | 1 |
| Danon, A; Rimon, G; Rosenstock, M; Rubin, M | 1 |
| Asai, F; Jakubowski, JA; Niitsu, Y; Sugidachi, A | 1 |
| Brandt, JT; Darstein, C; Jakubowski, JA; Jernberg, T; Naganuma, H; Payne, CD; Siegbahn, A; Wallentin, L; Winters, KJ | 1 |
| Lowry, DR; Malinin, AI; Meilman, H; Midei, MG; Serebruany, VL | 1 |
| Becka, M; Kubitza, D; Mueck, W; Zuehlsdorf, M | 1 |
| Gurbel, PA; Tantry, US | 2 |
| Bliden, KP; Gurbel, PA; Tantry, US | 1 |
| Brandt, JT; Farid, NA; Jakubowski, JA; Lachno, DR; Li, YG; Naganuma, H; Payne, CD; Weerakkody, GJ; Winters, KJ | 1 |
| Barnard, MR; Fox, ML; Frelinger, AL; Furman, MI; Jakubowski, JA; Li, Y; Linden, MD; Michelson, AD; Sugidachi, A; Winters, KJ | 1 |
| Antman, EM; Ardissino, D; Braunwald, E; De Servi, S; Gibson, CM; Gottlieb, S; McCabe, CH; Montalescot, G; Murphy, SA; Neumann, FJ; Riesmeyer, J; Ruzyllo, W; Weerakkody, G; Wiviott, SD | 1 |
| Bhatt, DL | 1 |
| Braun, OO; Erlinge, D; Jakubowski, JA; James, S; Siegbahn, A; Sugidachi, A; Varenhorst, C; Wallentin, L; Winters, KJ | 1 |
| Go, G; Gonzalez Della Valle, A; Lyman, S; Salvati, EA; Sharrock, NE | 1 |
| Brandt, JT; Farid, NA; Jakubowski, JA; Li, YG; Payne, CD; Salazar, DE; Small, DS; Winters, KJ | 2 |
| Yee, J | 1 |
| Paulus, W; Riggert, J; von Lewinski, F | 1 |
| Eikelboom, JW; Hankey, GJ; Langton, PE | 1 |
| Antman, EM; Braunwald, E; Chandna, H; Hasin, Y; Macias, W; McCabe, CH; Murphy, SA; Voitk, J; Widimsky, P; Wiviott, SD | 1 |
| Barker, CM; Price, MJ | 1 |
| Angiolillo, DJ; Bass, TA; Bates, ER | 1 |
| Abbate, R; Gensini, GF; Gori, AM; Marcucci, R | 1 |
| Cohen, M; Giugliano, R; Granger, CB; Gurbel, PA; Hoekstra, J; Hollander, JE; Manoukian, SV; Pollack, CV; Saucedo, JF | 1 |
| El-Gazzar, AB; Hafez, HN | 1 |
| Brandt, JT; Braun, OO; Erlinge, D; Jakubowski, JA; James, S; Johnell, M; Siegbahn, A; Varenhorst, C; Wallentin, L; Winters, KJ | 1 |
| Wiviott, SD | 1 |
| Becker, RC | 1 |
| Eikelboom, JW; Hirsh, J; Raju, NC | 1 |
| Ernest, CS; Rohatagi, S; Salazar, DE; Small, DS; Wallentin, L; Winters, KJ; Wrishko, RE | 1 |
| Calatzis, A | 1 |
| Kopyleva, O; Serebruany, V; Shalito, I | 1 |
| Toth, PP | 1 |
| Faxon, DP; Freedman, JE | 1 |
| Brandt, JT; Braun, OO; Erlinge, D; Jakubowski, JA; James, S; Olofsson, S; Siegbahn, A; Varenhorst, C; Wallentin, L; Winters, KJ | 1 |
| Antman, EM; Braunwald, E; Gibson, CM; McCabe, CH; Montalescot, G; Murphy, SA; Wiviott, SD | 1 |
| Antonino, MJ; Gurbel, PA; Mahla, E; Tantry, US | 1 |
| Butt, M; Lip, GY; Shantsila, E; Siddique, A | 1 |
| Brandt, JT; Braun, OO; Close, SL; Erlinge, D; James, S; Man, M; Siegbahn, A; Varenhorst, C; Walker, J; Wallentin, L; Winters, KJ | 1 |
| Cryer, B | 1 |
| Das, K; Das, P; Koshy, SK; Robinson, A | 1 |
| Price, MJ | 1 |
| Motovska, Z; Widimsky, P | 1 |
| Shil, AB; Strohm, MP | 1 |
| Barthélémy, O; Beygui, F; Collet, JP; Funck-Brentano, C; Hulot, JS; Montalescot, G; Pena, A; Silvain, J | 1 |
| Serebruany, VL | 1 |
| Eberli, FR; Roffi, M | 1 |
| Barnathan, ES; Bordes, P; Braunwald, E; Burton, P; Gibson, CM; Hricak, V; Markov, V; Mega, JL; Misselwitz, F; Mohanavelu, S; Oppenheimer, L; Poulter, R; Witkowski, A | 1 |
| Alban, S; Dingermann, T | 1 |
| Breitkreutz, J | 1 |
| Kumar, A; Roberts, DH | 1 |
| Dauerman, HL | 1 |
| Antman, EM; Braunwald, E; Buros, JL; Gibson, CM; Pride, YB; Tariq, MU; Wiviott, SD; Zorkun, C | 1 |
| Unger, EF | 1 |
| Ernest, CS; Farid, NA; Li, YG; Ni, L; Payne, CD; Salazar, DE; Small, DS; Winters, KJ; Wrishko, RE | 1 |
| Schrör, K | 1 |
| Collet, JP; Montalescot, G | 1 |
| Menon, V; Raymond, C | 1 |
| Solomon, S; Vacek, JL | 1 |
| Islam, AM; Patel, PM | 1 |
| Fareed, J; Jeske, WP; Mousa, SA | 1 |
| Aylward, PE; Behan, MW; Chew, DP | 1 |
| Bareiss, P; Kessler, L; Morel, O; Ohlmann, P | 1 |
| Chew, DP; Prakash, R; Wong, YW | 1 |
| Cohen, AT; Nandini, B; Ota, S; Wills, JO | 1 |
| Bauters, C; Bonello, L; Delhaye, C; Lablanche, JM; Lemesle, G; Maluenda, G; Sudre, A | 1 |
| Erdem, G; Flather, MD; Geisler, T | 1 |
| Cairns, JA; Eikelboom, JW; Hirsh, J; Paikin, JS | 1 |
| Shakib, S; Tadros, R | 1 |
| Gratsianskiĭ, NA | 1 |
| Aïssaoui, N; Danchin, N | 1 |
| Gurbel, PA; Mahla, E; Metzler, H; Tantry, US | 1 |
| Abbate, R; Giusti, B | 1 |
| Laizure, SC; Parker, RB | 1 |
| Ferrandis, R; Gómez-Luque, A; Llau, JV; Sierra, P | 1 |
| Abraham, NS; Antman, EM; Bhatt, DL; Bjorkman, DJ; Clark, CB; Furberg, CD; Hlatky, MA; Johnson, DA; Kahi, CJ; Laine, L; Mahaffey, KW; Quigley, EM; Scheiman, J; Sperling, LS; Tomaselli, GF | 2 |
| Capranzano, P; Dangas, G; Mehran, R; Stone, GW; Tamburino, C | 1 |
| Minarelli, M; Valgimigli, M | 1 |
| Frey, N; Ivandic, B | 1 |
| Ağırbaşlı, M; Cinçin, A; Güvenç, H | 1 |
| Endres, HG; Engelhardt, A; Kaiser, AF; Krüger, JC; Kusber, A; Lask, S; Mügge, A; Neubauer, H; Pepinghege, F | 1 |
| Angiolillo, DJ; Badimon, JJ; Baker, BA; Effron, MB; Frelinger, AL; Jakubowski, JA; Michelson, AD; Ojeh, CK; Saucedo, JF; Zhu, B | 1 |
| Cattaneo, M | 1 |
| Engelen, S; Sinnaeve, P; Van Damme, H; Verhamme, P | 1 |
| Hamm, CW; Rassaf, T | 1 |
| Smetana, GW; Srour, JF | 1 |
| Baty, SR; Griffith, CB; Phillippe, HM | 1 |
| Briongos Figuero, S; de Juan-Bagudá, J; Martí-Sánchez, D; Salido-Tahoces, L | 1 |
| Antman, EM; Braunwald, E; Contant, CF; Dalby, AJ; Giugliano, RP; Guo, J; Hochholzer, W; Montalescot, G; Wiviott, SD | 1 |
| Moliterno, DJ; Rajan, L | 1 |
| Dhanji, AR; Kirkby, NS; Leadbeater, PD; Milne, GL; Mitchell, JA; Thomas, S; Tucker, AT; Warner, TD | 1 |
| Chan, MV; Kirkby, NS; Leadbeater, PD; Mitchell, JA; Nylander, S; Warner, TD | 1 |
| Bonafede, M; Deitelzweig, SB; Gdovin Bergeson, J; Graham, J; Jing, Y; Liffmann, D; Makenbaeva, D | 1 |
| Rayoo, R; Sharma, N; van Gaal, WJ | 1 |
| Chen, SY; Gao, H; Ma, GF | 1 |
| Cayla, G; Collet, JP; Montalescot, G; O'Connor, SA; Silvain, J | 2 |
| Bae, JP; Cohen, DJ; Graham, JB; Magnuson, EA; Mauskopf, JA; Meadows, ES; Ramaswamy, K; Zagar, AJ | 1 |
| Basra, SS; Lakkis, NM; Tsai, P | 1 |
| Barakoti, M; Neupane, P; Pant, S; Ramesh, KC | 1 |
| Ikeda, Y; Isshiki, T; Kimura, T; Ogawa, H; Yokoi, H | 1 |
| Braunwald, E | 1 |
| Dahl, OE; Eriksson, BI; Friedman, RJ; Homering, M; Rosencher, N | 1 |
| Hsu, PI | 1 |
| Contractor, H; Ruparelia, N | 1 |
| Amore, C; Dell'Elba, G; Di Santo, A; Evangelista, V; Martelli, N; Piccoli, A; Totani, L | 1 |
| Chevtzoff, C; Fullerton, MD; Green, KA; Hardie, DG; Hawley, SA; Kemp, BE; Mustard, KJ; Peggie, MW; Ross, FA; Sakamoto, K; Schertzer, JD; Steinberg, GR; Walker, KJ; Zibrova, D | 1 |
| Dibattiste, PM; Ringwala, SM; Schneider, DJ | 1 |
| Angiolillo, DJ; Azmoon, S | 1 |
| Halperin, JL; Varughese, CJ | 1 |
| Bessereau, J; Bonello, L; Camoin-Jau, L; Paganelli, F; Uhry, S | 1 |
| Goodnough, LT; Lenarz, LA; Levy, JH; Poston, RS; Short, MA; Smith, PK; Weerakkody, GJ | 1 |
| Gupta, A; Hirst, J; McKay, RG; Rai, M; Ruaño, G; Seip, RL; Thompson, PD | 1 |
| Heptinstall, S; Joshi, R; Wijeyeratne, YD | 1 |
| Angiolillo, DJ; Baker, BA; Heiselman, DE; Jakubowski, JA; Li, W; Logan, DK; Price, MJ; Walder, JS; Winters, KJ | 1 |
| Ahmad, S; Storey, RF | 1 |
| Bessereau, J; Bonello, L; Camoin-Jau, L; Laine, M; Paganelli, F; Sébastien, A | 1 |
| Bhatt, DL; Kar, S | 1 |
| Callahan, S; Goldsberry, A; Kim, G; Yoo, S | 1 |
| Alexander, KP; Foody, JM; Funk, M; Granger, CB; Li, L; Lopes, RD; Peterson, ED; Wang, TY | 1 |
| Limper, U; Lynch, J | 1 |
| Huber, K | 1 |
| Ardissino, D; Armstrong, PW; Aylward, PE; Bhatt, DL; Boden, WE; Brown, EB; Cinteză, M; Clemmensen, P; Corbalan, R; Cornel, JH; Dalby, AJ; Fox, KA; Gasparovic, V; Goodman, SG; Gottlieb, S; Goudev, AR; Gurbel, PA; Hamm, C; Hochman, JS; Huber, K; Leiva-Pons, JL; Lokhnygina, Y; Martinez, F; McGuire, DK; McLendon, RC; Merkely, B; Nicolau, JC; Ohman, EM; Oto, A; Parkhomenko, A; Pavlides, G; Prabhakaran, D; Roe, MT; Ruzyllo, W; Topacio, GO; Tseng, CD; White, HD; Winters, KJ | 1 |
| Badimon, JJ; Becker, EM; Bütehorn, U; Kast, R; Klipp, A; Laux, V; Lücker, C; Perzborn, E | 1 |
| Choi, KN; Chung, SR; Do, U; Jang, JS; Jin, HY; Kim, DK; Kim, DS; Kim, HJ; Seo, JS; Yang, TH | 1 |
| Armstrong, PW; Brown, E; Chan, MY; Cornel, JH; Erlinge, D; Fox, KA; Goodman, SG; Gurbel, PA; Huber, K; Jakubowski, JA; Neely, B; Neely, M; Ohman, EM; Prabhakaran, D; Roe, MT; Tantry, US; White, HD; Zhou, C | 1 |
| Abtan, J; Aubry, P; Barthélémy, O; Belle, L; Beygui, F; Boueri, Z; Carrié, D; Cayla, G; Collet, JP; Cuisset, T; Elhadad, S; Henry, P; Kerneis, M; Monségu, J; Montalescot, G; Motreff, P; O'Connor, SA; Pouillot, C; Rangé, G; Rousseau, H; Sabouret, P; Saint-Etienne, C; Silvain, J; Van Belle, E; Vicaut, E | 1 |
| Badimon, JJ; Elmariah, S; Fuster, V; Giannarelli, C; Jakubowski, JA; Santos-Gallego, C; Sartori, S; Small, DS; Viles-Gonzalez, JF; Vorchheimer, DA; Zafar, MU | 1 |
| Chevalier, B; Diletti, R; Dorange, C; Farooq, V; Garcia-Garcia, HM; Miquel-Hebert, K; Onuma, Y; Rapoza, R; Serruys, PW; Sudhir, K; Veldhof, S | 1 |
| Coste, P; Gerbaud, E; Seguy, B | 1 |
| Kiss, RG | 1 |
| Chen, F; Kent, KM; Kitabata, H; Loh, JP; Pendyala, LK; Pichard, AD; Satler, LF; Suddath, WO; Torguson, R; Waksman, R | 1 |
| Crosby-Nwaobi, R; Drozdov, I; Dudek, K; Kaudewitz, D; Kiechl, S; King, A; Kirkby, NS; Langley, SR; Markus, HS; Mayr, M; Mitchell, JA; Prokopi, M; Sivaprasad, S; Warner, TD; Willeit, P; Zampetaki, A | 1 |
| Can, MM; Dinicolantonio, JJ; Goto, S; Serebruany, VL | 1 |
| Aronow, WS | 2 |
| Agewall, S; Andreotti, F; Atar, D; Cattaneo, M; Collet, JP; Grove, EL; Huber, K; Husted, S; Kjeldsen, K; Lip, GY; Morais, J; Pathak, A; Rosano, G; Storey, RF; Verheugt, FW; Wassmann, S | 1 |
| Kastrati, A; Martischnig, A; Mayer, K; Mehilli, J; Sarafoff, N; Sibbing, D; Wealer, J | 1 |
| Gurbel, PA; Jeong, YH; Kubica, J; Navarese, EP; Tantry, US | 1 |
| Erlinge, D; Larsson, J; Ohman, J; Salmi, H; Torngren, K | 1 |
| Angiolillo, DJ; Bailey, WL; Baker, BA; Bliden, KP; Gurbel, PA; Jakubowski, JA; Jeong, YH; Kereiakes, DJ; Lasseter, KC; Logan, DK; Maa, JF; Nolin, TD; Ojeh, CK; Tantry, US; White, A | 1 |
| Bassand, JP; Bhatt, DL; Bode, C; Braunwald, E; Burton, P; Chakrabarti, AK; Cohen, M; Gibson, CM; Goto, S; Mega, J; Mohanavelu, S; Stone, G; Verheugt, FW | 1 |
| Gremmel, T; Kopp, CW; Koppensteiner, R; Panzer, S; Seidinger, D; Steiner, S | 1 |
| Franken, CC; Kaiser, AF; Krüger, JC; Mügge, A; Neubauer, H; Overbeck, K | 1 |
| Apostolakis, S; Lip, GY; Shantsila, E | 1 |
| Becka, M; Gouya, G; Kapiotis, S; Kubitza, D; Mueck, W; Wolzt, M | 1 |
| Finsterer, J; Stöllberger, C | 1 |
| Diener, HC | 1 |
| Bates, P; Culpan, P; El-Daly, I; Reidy, J | 1 |
| Ardissino, D; Armstrong, PW; Aylward, PE; Bassand, JP; Boden, WE; Dalby, AJ; Fox, KA; Goodman, SG; Gottlieb, S; Hochman, JS; Martinez, F; McGuire, DK; Ohman, EM; Prabhakaran, D; Roe, MT; Stevens, SR; White, HD; Winters, KJ | 1 |
| Can, MM; Dinicolantonio, JJ; Kuliczkowski, W; Pershukov, IV; Serebruany, VL | 1 |
| Al-Majzoub, O; Assiri, A; Donovan, JL; Kanaan, AO; Silva, M | 1 |
| Angiolillo, DJ; Bass, TA; Darlington, A; Desai, B; Franchi, F; Guzman, LA; Muñiz-Lozano, A; Patel, R; Rollini, F; Tello-Montoliu, A; Thano, E; Wilson, RE | 1 |
| Dinicolantonio, JJ; Norgard, NB | 1 |
| Aslam, R; Ducrocq, N; Gerard, A; Kimmoun, A; Levy, B; Perez, P; Thivilier, C | 1 |
| Kansal, AR; Pokora, T; Sorensen, SV; Zheng, Y | 1 |
| Ackman, ML; Bauer, RD; Bell, AD; Cartier, R; Chan, WS; Douketis, J; Mehta, SR; Roussin, A; Schnell, G; Tanguay, JF; Verma, S; Wong, G | 1 |
| Cameron, C; Carrier, M; Castellucci, LA; Clifford, T; Coyle, D; Gandara, E; Le Gal, G; Rodger, MA; Wells, G; Wells, PS | 1 |
| Grove, EL; Würtz, M | 1 |
| He, B; Kun, L; Liu, X; Wu, B | 1 |
| Curkovic, I; Egbring, M; Kullak-Ublick, GA | 1 |
| Dugdale, M; Fabian, TC; Gordon, JL; Lee, MD | 1 |
| Acharji, S; Kaluski, E; Lakshmanadoss, U; Rudzinski, W; Stapleton, DD | 1 |
| Barbar, S; Milan, M; Pesavento, R; Prandoni, P; Vedovetto, V | 1 |
| Adsett, G; Jayasinghe, R; Markham, R | 1 |
| Becker, RC; Breithardt, G; Califf, RM; Fox, KA; Goodman, SG; Hacke, W; Halperin, JL; Hankey, GJ; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Singer, DE; Stevens, SR; White, HD | 1 |
| Antman, EM; Braunwald, E; Cannon, CP; Kohli, P; Murphy, SA; Udell, JA; Wiviott, SD | 1 |
| Angiolillo, DJ; Bass, TA; Darlington, A; Desai, B; Ferreiro, JL; Guzman, LA; Patel, R; Rollini, F; Tello-Montoliu, A; Ueno, M | 1 |
| Arrich, J; Gouya, G; Gurbel, PA; Huber, K; Pirker-Kees, A; Siller-Matula, JM; Verheugt, FW; Wolzt, M | 1 |
| Angiolillo, DJ; Baker, BA; Heiselman, DE; Jakubowski, JA; Li, W; Price, MJ | 1 |
| Arntz, HR; Boudriot, E; Garlichs, C; Helms, TM; Hoffmann, S; Ince, H; Klingenheben, T; Schäfer, A; Silber, S; Weil, J; Zugck, C | 1 |
| Ay, C; Badr Eslam, R; Eichelberger, B; Gremmel, T; Lang, IM; Panzer, S; Posch, F | 1 |
| Henke, C; Strasser, RH; Wiedemann, S | 1 |
| Alexander, T; Babu, PR; Dani, S; Dasbiswas, A; Hiremath, S; Nayak, R; Patel, T; Pathak, K; Prakash, VS; Rao, MS; Singh, DP; Srivastava, A; Tyagi, S; Vijayvergiya, R; Yadav, MK | 1 |
| Hirschl, MM | 1 |
| Gupta, K; Singh, D; Vacek, JL | 1 |
| Hosokawa, K; Koide, T; Maruyama, I; Miura, N; Ohnishi, T; Sameshima, H; Tanaka, KA | 1 |
| Gnall, EM; Ice, DS; Kowey, PR; Shapiro, TA | 1 |
| Duraj, L; Fedor, M; Fedorová, J; Galajda, P; Kovář, F; Kubisz, P; Mokáň, M; Samoš, M; Šimonová, R; Staško, J | 1 |
| Sun, K; Tian, S; Wang, Y; Zou, Y | 1 |
| Brighton, TA; Davidson, BL; Gebel, M; Lensing, AW; Lyons, RM; Prins, MH; Rehm, J; Verheijen, S | 1 |
| Al-Attar, N; Amour, J; Ascione, R; Collet, JP; Falk, V; Huber, K; Leite-Moreira, AF; Sousa-Uva, M; Storey, R; Taggart, D | 1 |
| Isshiki, T; Kimura, T; Kitagawa, K; Miyazaki, S; Nakamura, M; Nanto, S; Nishikawa, M; Ogawa, H; Saito, S; Takayama, M; Yokoi, H | 1 |
| Bangalore, S; Biondi-Zoccai, G; Cerrato, E; Chatterjee, S; D'Ascenzo, F; DiNicolantonio, JJ; Fuchs, FD; Lavie, CJ; Meier, P; Niazi, AK; Norgard, NB; O'Keefe, JH; Packard, KA; Serebruany, VL | 1 |
| Gislason, G; Sørensen, R | 1 |
| Corrada, E; Ferri, M; Savonitto, S | 1 |
| Cotté, FE; Durand-Zaleski, I; Gaudin, AF; Kachaner, I; Kongnakorn, T; Lanitis, T | 1 |
| Droppa, M; Gawaz, M; Geisler, T; Karathanos, A; Metzger, J; Müller, K; Rath, D; Schäffeler, E; Schwab, M; Stimpfle, F; Tavlaki, E; Winter, S | 1 |
| Abbate, R; Antoniucci, D; Bellandi, B; Carrabba, N; Gensini, GF; Giurlani, L; Marcucci, R; Migliorini, A; Parodi, G; Valenti, R | 1 |
| Takahashi, J | 1 |
| Abtan, J; Anzaha, G; Barthélémy, O; Beygui, F; Brugier, D; Cayla, G; Charland, SL; Collet, JP; Galier, S; Gallois, V; Hulot, JS; Kerneis, M; Montalescot, G; O'Connor, SA; Silvain, J; Stanek, EJ | 1 |
| Costigan, T; Iqbal, K; Lopez-Sendon, J; Ramos, Y; Widimsky, P; Wilcox, R | 1 |
| Engel, G; Kong, MH; Mead, RH; Patrawala, RA; Winkle, RA | 1 |
| Guo, X; Li, L; Tang, B; Xu, G; Zhang, Y; Zhou, X | 1 |
| Fauchère, I; Schreiber, P; Wyss, C | 1 |
| Eichinger, S; Gouya, G; Kapiotis, S; Kyrle, PA; Litschauer, B; Mayer, P; Smerda, L; Weisshaar, S; Wolzt, M | 1 |
| Ahn, JH; Gurbel, P; Jeong, YH; Kim, KH; Tantry, US | 1 |
| Nakamura, M; Saito, S | 1 |
| Vengoechea, F | 1 |
| Christ, G; Dechant, C; Francesconi, M; Grohs, K; Podczeck-Schweighofer, A; Siller-Matula, JM | 1 |
| Chieffo, A; Colombo, A | 1 |
| Braunwald, E; Cohen, DJ; Cutlip, DE; Dauerman, HL; Driscoll-Shempp, P; Garratt, KN; Hermiller, J; Holmes, DR; Kandzari, DE; Kereiakes, DJ; Krucoff, MW; Lee, DP; Massaro, JM; Mauri, L; Normand, SL; Pow, TK; Rinaldi, MJ; Simon, DI; Steg, PG; Ver Lee, P; Wiviott, SD; Yeh, RW | 1 |
| Allocco, DJ; Christen, T; Garratt, KN; Jenkins, RG; Kereiakes, DJ; Lee, DP; Mauri, L; Pow, TK; Weaver, WD; Winters, KJ | 2 |
| Collet, JP; Montalescot, G; Silvain, J | 1 |
| Alber, H; Buser, P; Conen, D; Eberli, F; Galatius, S; Gilgen, N; Hoffmann, A; Jeger, R; Kaiser, C; Kurz, DJ; Moccetti, T; Müller, C; Naber, C; Pedrazzini, G; Pfisterer, M; Rickenbacher, P; Rickli, H; Skov Jensen, J; Steiner, M; Vogt, DR; Von Felten, S; Vuillomenet, A; Wadt Hansen, K; Wanitschek, M; Weilenmann, D | 1 |
| Anderson, JL; Bates, ER; Bode, C; Granger, CB; Huber, K; Kristensen, SD; Lopez Sendon, JL; Ohman, EM; Steg, PG; Tubaro, M; Valgimigli, M; Wallentin, L | 1 |
| Huynh, K | 1 |
| Forslund, T; Hjemdahl, P; Holmström, M; Johnsson, H; von Euler, M; Wettermark, B | 1 |
| Lhermusier, T; Waksman, R | 1 |
| Bultas, J | 1 |
| Helft, G | 1 |
| Calıskan, A; Demirtas, S; Guclu, O; Kaplan, I; Karahan, O; Tezcan, O; Yavuz, C; Yazıcı, S | 1 |
| Amsallem, M; Bal dit Sollier, C; Dillinger, JG; Drouet, L; Henry, P; Manzo-Silberman, S; Sideris, G; Voicu, S | 1 |
| Keaney, JF | 1 |
| Guyatt, G; Spencer, FA | 1 |
| Steg, PG; Wiviott, SD | 1 |
| Kereiakes, DJ; Mauri, L; Yeh, RW | 1 |
| Sipahi, I | 1 |
| Dohan, JL | 1 |
| Marrs, JC | 1 |
| Jeger, R; Kaiser, C; Pfisterer, M | 1 |
| Tomoda, H | 1 |
| Boyce, JA; Laidlaw, TM | 1 |
| Buch, AN; Shah, AH | 1 |
| Jeger, RV; Pfisterer, ME | 1 |
| Abdellatif, KR; Azouz, AA; Fadaly, WA | 1 |
| Gu, TT; Huang, BB; Ji, JZ; Jia, YM; Mi, QY; Tai, T; Xie, HG; Zhang, MR; Zhou, H | 1 |
| Ge, PX; Gu, TT; Huang, BB; Ji, JZ; Jia, YM; Li, YF; Mi, QY; Tai, T; Xie, HG; Zhou, H; Zhu, T | 1 |
99 review(s) available for aspirin and thiophenes
| Article | Year |
|---|---|
Pharmacology of the interaction between platelets and vessel wall.
Topics: Animals; Aspirin; Blood Platelets; Blood Vessels; Dextrans; Diltiazem; Dipyridamole; Epoprostenol; Humans; Imidazoles; Ketanserin; Piperidines; Pyrazoles; Pyrazolones; Sulfinpyrazone; Sulfonamides; Thiophenes; Ticlopidine | 1986 |
[Platelet function inhibitors in peripheral arteriopathies].
Topics: Adrenal Cortex Hormones; Adrenergic alpha-Antagonists; Anti-Inflammatory Agents; Arachidonic Acid; Arachidonic Acids; Arteriosclerosis Obliterans; Aspirin; Blood Platelets; Calcium Channel Blockers; Clinical Trials as Topic; Cyclic AMP; Dipyridamole; Extremities; Heparin; Humans; Imidazoles; Prostaglandins; Prostanoic Acids; Pyrazoles; Pyrazolones; Quinacrine; Thiophenes; Thromboembolism; Thrombosis; Ticlopidine; Vascular Diseases | 1986 |
[Thrombosis in various diseases: myocardial infarct].
Topics: Angioplasty, Balloon; Aspirin; Dipyridamole; Humans; Myocardial Infarction; Platelet Aggregation; Thiophenes; Thrombosis; Ticlopidine | 1986 |
Antiplatelet drugs in the management of patients with thrombotic disorders.
Topics: Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Blood Coagulation Disorders; Blood Platelets; Catheterization; Cerebrovascular Disorders; Coronary Disease; Dipyridamole; Glomerulonephritis; Humans; Sulfinpyrazone; Suloctidil; Thiophenes; Thrombophlebitis; Thrombosis; Ticlopidine; Vascular Diseases; Vascular Surgical Procedures | 1986 |
Clinical trials evaluating platelet-modifying drugs in patients with atherosclerotic cardiovascular disease and thrombosis.
Topics: Anticoagulants; Aspirin; Blood Platelets; Blood Vessel Prosthesis; Cardiovascular Diseases; Clinical Trials as Topic; Dipyridamole; Double-Blind Method; Female; Glomerulonephritis; Graft Occlusion, Vascular; Heart Valve Prosthesis; Humans; Ischemic Attack, Transient; Male; Myocardial Infarction; Postoperative Complications; Random Allocation; Sulfinpyrazone; Thiophenes; Ticlopidine | 1986 |
[Role of antiaggregant platelet drugs in thromboembolism].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Anti-Bacterial Agents; Aspirin; Cerebrovascular Disorders; Dextrans; Dipyridamole; Humans; Mitral Valve; Platelet Aggregation; Platelet Function Tests; Pyridines; Pyridinolcarbamate; Random Allocation; Sulfinpyrazone; Suloctidil; Thiophenes; Thromboembolism; Ticlopidine | 1981 |
[Pharmacology of anti-platelet agents].
Topics: Animals; Anticoagulants; Aspirin; Blood Platelets; Cyclic AMP; Cyclooxygenase Inhibitors; Dipyridamole; Epoprostenol; Female; Fibrinolytic Agents; Humans; In Vitro Techniques; Intestinal Absorption; Kinetics; Male; Papio; Platelet Aggregation; Prostaglandin Antagonists; Rabbits; Sulfinpyrazone; Thiophenes; Thrombosis; Thromboxane A2; Ticlopidine | 1983 |
Chemoprevention of colon cancer by dietary administration of naturally-occurring and related synthetic agents.
Topics: Allyl Compounds; Anethole Trithione; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Arachidonic Acids; Aspirin; Colon; Colonic Neoplasms; Dinoprostone; Disulfides; Eflornithine; Food, Fortified; Ibuprofen; Intestinal Mucosa; Ornithine Decarboxylase; Ornithine Decarboxylase Inhibitors; Piroxicam; Pyrazines; Thiones; Thiophenes | 1997 |
Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity.
Topics: Adenosine Diphosphate; Adult; Animals; Aspirin; Biotransformation; Clinical Trials, Phase I as Topic; Clopidogrel; Collagen; Drug Evaluation, Preclinical; Drug Synergism; Fibrinolytic Agents; Hemostasis; Humans; Male; Membrane Proteins; Molecular Structure; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Purinergic P2 Receptor Antagonists; Pyridines; Rats; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thiophenes; Thrombin; Thrombosis; Ticlopidine | 2005 |
Aspirin and clopidogrel resistance: consideration and management.
Topics: Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Restenosis; Drug Resistance; Humans; Membrane Proteins; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine | 2006 |
Prasugrel.
Topics: Adenosine Diphosphate; Animals; Aspirin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase III as Topic; Clopidogrel; Collagen; Coronary Disease; Drug Evaluation, Preclinical; Drug Resistance; Drug Synergism; Drug Therapy, Combination; Drugs, Investigational; Humans; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Purinergic P2 Receptor Antagonists; Pyridines; Rats; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine | 2006 |
Potent anticoagulants are associated with a higher all-cause mortality rate after hip and knee arthroplasty.
Topics: Anesthesia, Conduction; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Azetidines; Benzylamines; Fondaparinux; Heparin, Low-Molecular-Weight; Humans; Intermittent Pneumatic Compression Devices; Morpholines; Platelet Aggregation Inhibitors; Polysaccharides; Pulmonary Embolism; Risk Assessment; Risk Factors; Rivaroxaban; Thiophenes; Treatment Outcome; Warfarin | 2008 |
Will prasugrel supersede clopidogrel for acute coronary syndromes?
Topics: Acute Coronary Syndrome; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Coronary Artery Bypass; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Thiophenes; Ticlopidine | 2008 |
Clinical profile of prasugrel, a novel thienopyridine.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes | 2008 |
Treatment strategies in non-ST-elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention: an evidence-based review of clinical trial results and treatment guidelines: report on a roundtable discussion.
Topics: Acute Coronary Syndrome; Algorithms; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cardiovascular Agents; Clinical Trials as Topic; Clopidogrel; Emergency Treatment; Evidence-Based Medicine; Fibrinolytic Agents; Hirudins; Humans; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Hemorrhage; Practice Guidelines as Topic; Prasugrel Hydrochloride; Recombinant Proteins; Risk Assessment; Stents; Thiophenes; Thrombosis; Ticlopidine | 2008 |
Intensity of antiplatelet therapy in patients with acute coronary syndromes and percutaneous coronary intervention: the promise of prasugrel?
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombosis; Ticlopidine | 2008 |
Biological and pharmacological aspects of perioperative hemorrhagic complications associated with oral platelet-directed antithrombotic agents. Focus on isolated coronary artery bypass grafting and oral irreversible P2Y(12) receptor antagonists.
Topics: Administration, Oral; Aspirin; Coronary Artery Bypass; Hemostasis; Hemostasis, Surgical; Humans; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes | 2009 |
Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future.
Topics: Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; History, 20th Century; History, 21st Century; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Stents; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2008 |
Prasugrel development - claims and achievements.
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Animals; Aspirin; Blood Platelets; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Drug Administration Schedule; Drug Discovery; Drug Resistance; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Research Design; Risk Assessment; Stents; Thiophenes; Ticlopidine; Treatment Outcome | 2009 |
The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aspirin; Humans; Life Style; Myocardial Infarction; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Secondary Prevention; Thiophenes | 2009 |
Response variability and the role of platelet function testing.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2009 |
New antiplatelet drugs: beyond aspirin and clopidogrel.
Topics: Adenosine; Adenosine Monophosphate; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Drug Design; Humans; Imines; Lactones; Naphthalenes; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Propionates; Purinergic P2 Receptor Antagonists; Pyridines; Thiophenes; Ticagrelor; Ticlopidine | 2009 |
Management of patients with high gastrointestinal risk on antiplatelet therapy.
Topics: Aspirin; Clopidogrel; Gastrointestinal Hemorrhage; Humans; Peptic Ulcer; Peptic Ulcer Hemorrhage; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Risk Factors; Thiophenes; Ticlopidine | 2009 |
Prasugrel: newest antiplatelet agent and its emerging role in management of acute coronary syndrome and percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Resistance; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Thiophenes; Ticlopidine | 2009 |
Bedside evaluation of thienopyridine antiplatelet therapy.
Topics: Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Clinical Trials as Topic; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Resistance; Drug Therapy, Combination; Humans; Mass Screening; Myocardial Infarction; Nephelometry and Turbidimetry; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Function Tests; Point-of-Care Systems; Prasugrel Hydrochloride; Prodrugs; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Thrombelastography; Ticlopidine; United States | 2009 |
Improving outcomes in patients undergoing percutaneous coronary intervention: role of prasugrel.
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Thrombosis; Diabetes Complications; Drug Resistance; Drug Therapy, Combination; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Risk Factors; Stents; Thiophenes; Ticlopidine; Treatment Outcome | 2009 |
Aggressive chronic platelet inhibition with prasugrel and increased cancer risks: revising oral antiplatelet regimens?
Topics: Animals; Aspirin; Clopidogrel; Colonic Neoplasms; Gastrointestinal Hemorrhage; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine | 2009 |
Diabetes and acute coronary syndromes.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Blood Glucose; Clopidogrel; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Enoxaparin; Hirudins; Humans; Hypoglycemic Agents; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Recombinant Proteins; Thiophenes; Thrombosis; Ticlopidine | 2009 |
[Technological and biopharmaceutical aspects. Antiplatelet agents for oral administration].
Topics: Administration, Oral; Animals; Aspirin; Clopidogrel; Dipyridamole; Humans; Patents as Topic; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2009 |
Challenges in oral antiplatelet therapy: ST-segment elevation myocardial infarction.
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Administration Schedule; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2009 |
Dual antiplatelet therapy in coronary artery disease: a case-based approach.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stents; Thiophenes; Ticlopidine | 2009 |
Preventing serious sequelae after an acute coronary syndrome: the consequences of thrombosis versus bleeding with antiplatelet therapy.
Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Risk Factors; Thiophenes; Thrombosis; Ticlopidine | 2010 |
Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials, Phase III as Topic; Clopidogrel; Drug Evaluation, Preclinical; Drug Therapy, Combination; Hemorrhage; Humans; Ischemia; Kidney Failure, Chronic; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine | 2010 |
The role of antiplatelet therapy in the secondary prevention of coronary artery disease.
Topics: Adenosine; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Interactions; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Secondary Prevention; Thiophenes; Thromboxane A2; Ticagrelor; Ticlopidine | 2010 |
Diabetes and the platelet: toward new therapeutic paradigms for diabetic atherothrombosis.
Topics: Acute Coronary Syndrome; Apoptosis; Aspirin; Blood Platelets; Clopidogrel; Diabetes Complications; Diabetes Mellitus; Glycoproteins; Humans; Models, Biological; Piperazines; Platelet Activation; Prasugrel Hydrochloride; Receptors, Purinergic P2Y12; Thiophenes; Thromboplastin; Thrombosis; Ticlopidine | 2010 |
Antiplatelet therapy in percutaneous coronary intervention: recent advances in oral antiplatelet agents.
Topics: Adenosine; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Pyridines; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2010 |
VTE prophylaxis for the medical patient: where do we stand? - a focus on cancer patients.
Topics: Anticoagulants; Aspirin; Fondaparinux; Heparin; Heparin, Low-Molecular-Weight; Humans; Morpholines; Neoplasms; Polysaccharides; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism; Warfarin | 2010 |
Dosing strategies for antiplatelet therapy in percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clinical Protocols; Clopidogrel; Drug Administration Schedule; Drug Monitoring; Hemorrhage; Humans; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Risk Assessment; Risk Factors; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome | 2010 |
What goes into a major acute coronary syndrome trial and what will future trials look like?
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clinical Trials as Topic; Clopidogrel; Cyclic N-Oxides; Eptifibatide; Heart Diseases; Humans; Peptides; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Research Design; Research Support as Topic; Risk Factors; Sample Size; Thiophenes; Ticagrelor; Ticlopidine; United Kingdom | 2010 |
New antithrombotic agents--insights from clinical trials.
Topics: Adenosine; Anticoagulants; Aspirin; Clopidogrel; Coronary Thrombosis; Coumarins; Fibrinolytic Agents; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Thromboembolism; Ticagrelor; Ticlopidine | 2010 |
Clot prevention--common questions about medications.
Topics: Anticoagulants; Aspirin; Benzimidazoles; Dabigatran; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; International Normalized Ratio; Morpholines; Pharmacogenetics; Pyridines; Risk Factors; Rivaroxaban; Thiophenes; Thrombosis; Venous Thromboembolism | 2010 |
[Antiplatelet therapy in coronary heart disease. Some problems and achivements].
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Blood Platelets; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug Interactions; Drug Resistance; Gastrointestinal Hemorrhage; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Polymorphism, Genetic; Prasugrel Hydrochloride; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Receptor, PAR-1; Thiophenes; Ticagrelor; Ticlopidine; United States; United States Food and Drug Administration | 2010 |
Pharmacologic therapy for non ST-segment elevation acute coronary syndromes: focus on antithrombotic therapy.
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Disease Management; Drug Synergism; Drug Therapy, Combination; Enoxaparin; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Heparin; Hirudins; Humans; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Recombinant Proteins; Thiophenes; Ticagrelor; Ticlopidine | 2010 |
Controversies in oral antiplatelet therapy in patients undergoing aortocoronary bypass surgery.
Topics: Administration, Oral; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Thiophenes; Thrombosis; Ticlopidine | 2010 |
A comparison of the metabolism of clopidogrel and prasugrel.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Carboxylic Ester Hydrolases; Clopidogrel; Cytochrome P-450 Enzyme System; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Thiophenes; Thrombosis; Ticlopidine | 2010 |
Prevention of the renarrowing of coronary arteries using drug-eluting stents in the perioperative period: an update.
Topics: Aspirin; Blood Loss, Surgical; Clopidogrel; Coronary Thrombosis; Coronary Vessels; Drug-Eluting Stents; Humans; Myocardial Revascularization; Perioperative Care; Perioperative Period; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2010 |
ACCF/ACG/AHA 2010 Expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aryl Hydrocarbon Hydroxylases; Aspirin; Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Interactions; Drug Therapy, Combination; Gastrointestinal Hemorrhage; Histamine H2 Antagonists; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Factors; Thienopyridines; Thiophenes; Ticlopidine | 2010 |
ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aryl Hydrocarbon Hydroxylases; Aspirin; Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Interactions; Drug Therapy, Combination; Gastrointestinal Hemorrhage; Histamine H2 Antagonists; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Factors; Thienopyridines; Thiophenes; Ticlopidine | 2010 |
[New approaches and indications for the analysis of platelet function in cardiology].
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Interactions; Hemorrhage; Humans; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
[Novel agents in antiplatelet therapy].
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Humans; Lactones; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Pyridines; Receptors, Thrombin; Thiophenes; Ticagrelor; Ticlopidine | 2010 |
Antiplatelet therapy in the perioperative period.
Topics: Aspirin; Clopidogrel; Humans; Perioperative Period; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2010 |
[Coronary heart disease - what is of importance after coronary intervention?].
Topics: Adenosine; Aftercare; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Schedule; Drug Approval; Drug Therapy, Combination; Drug-Eluting Stents; Gastrointestinal Hemorrhage; Humans; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Proton Pump Inhibitors; Stents; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
Triple therapy in hospitalized patients: facts and controversies.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Hospitalization; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Warfarin | 2011 |
Triple therapy: boon or bane for high-risk CV patients?
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Warfarin | 2011 |
Beyond aspirin and clopidogrel: is there a need for additional antiplatelet therapy in ACS?
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Quinazolinones; Receptors, Purinergic P2Y12; Sulfonamides; Tetrazoles; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
Antiplatelet options for secondary prevention in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Risk Factors; Secondary Prevention; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
Safety and efficacy of antiplatelet and antithrombotic therapy in acute coronary syndrome patients with chronic kidney disease.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Chronic Disease; Clinical Trials as Topic; Clopidogrel; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Heparin; Hirudins; Humans; Kidney Diseases; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Recombinant Proteins; Thiophenes; Ticagrelor; Ticlopidine; Uremia | 2011 |
Unstable angina and non-ST elevation myocardial infarction.
Topics: Acute Coronary Syndrome; Adenosine; Angina, Unstable; Anticoagulants; Aspirin; Clopidogrel; Coronary Angiography; Echocardiography; Electrocardiography; Humans; Myocardial Infarction; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
Advances in antiplatelet therapy for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Emergency Treatment; Female; Humans; Male; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Sulfonamides; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
Current antiplatelet options for NSTE-ACS patients.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Biological Availability; Clopidogrel; Comparative Effectiveness Research; Drug Monitoring; Drug Synergism; Drug Therapy, Combination; Electrocardiography; Humans; Pharmacovigilance; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y; Risk Assessment; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
Switching antiplatelet regimens: alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: a review of the literature and practical considerations for the interventional cardiologist.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Interactions; Drug Substitution; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervention; Pharmacogenetics; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options.
Topics: Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Hemorrhage; Humans; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thrombolytic Therapy; Ticlopidine; Warfarin | 2012 |
Latest evidence in personalized antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Aryldialkylphosphatase; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Interactions; Drug Resistance; Evidence-Based Medicine; Genotype; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Postoperative Complications; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine | 2012 |
Ticagrelor: a P2Y12 antagonist for use in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Blood Platelets; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Humans; Kaplan-Meier Estimate; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Product Surveillance, Postmarketing; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
Development and clinical use of prasugrel and ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Animals; Aspirin; Blood Platelets; Clopidogrel; Drug Design; Hemorrhage; Hemostasis; Humans; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
Tailoring antiplatelet therapy: a step toward individualized therapy to improve clinical outcome?
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Blood Platelets; Clopidogrel; Coronary Thrombosis; Drug Interactions; Drug Resistance; Genotype; Hemorrhage; Humans; Patient Selection; Percutaneous Coronary Intervention; Pharmacogenetics; Phenotype; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Precision Medicine; Predictive Value of Tests; Receptors, Purinergic P2Y12; Risk Assessment; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
Anticoagulants for the treatment of acute coronary syndrome in the era of new oral agents.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Antithrombins; Aspirin; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Drug Therapy, Combination; Factor Xa Inhibitors; Hemorrhage; Heparin; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Ticlopidine; Warfarin | 2012 |
The management of antithrombotic medication in skin surgery.
Topics: Anticoagulants; Antithrombins; Aspirin; Benzimidazoles; beta-Alanine; Dabigatran; Dermatologic Surgical Procedures; Fibrinolytic Agents; Fondaparinux; Heparin, Low-Molecular-Weight; Humans; Morpholines; Platelet Aggregation Inhibitors; Polysaccharides; Risk Assessment; Rivaroxaban; Thienopyridines; Thiophenes; Vitamin K; Warfarin | 2012 |
Clopidogrel in coronary artery disease: update 2012.
Topics: Adenosine; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
[Novel agents for antithrombotic therapy in cardiology].
Topics: Adenosine; Administration, Oral; Anticoagulants; Aspirin; Clopidogrel; Coumarins; Fibrinolytic Agents; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Thrombolytic Therapy; Ticagrelor; Ticlopidine | 2012 |
Antiplatelet drug use in patients with non-ST-segment elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy.
Topics: Adenosine; Aspirin; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Clopidogrel; Dabigatran; Drug Interactions; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Warfarin | 2013 |
Pharmacokinetic considerations for antithrombotic therapies in stroke.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Cilostazol; Clopidogrel; Factor Xa; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Stroke; Tetrazoles; Thiophenes; Thrombin; Ticlopidine; Vitamin K | 2013 |
Thromboprophylaxis in patients with pelvic and acetabular fractures: A short review and recommendations.
Topics: Acetabulum; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Coumarins; Dabigatran; Fondaparinux; Fractures, Bone; Heparin; Humans; Mass Screening; Morpholines; Multiple Trauma; Pelvis; Polysaccharides; Pulmonary Embolism; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Thiophenes; Vena Cava Filters; Venous Thromboembolism | 2013 |
Use of antiplatelet drugs in the treatment of acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2013 |
Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Data Interpretation, Statistical; Databases, Bibliographic; Double-Blind Method; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Clopidogrel, prasugrel, or ticagrelor? a practical guide to use of antiplatelet agents in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Decision Support Techniques; Drug Therapy, Combination; Humans; Induction Chemotherapy; Maintenance Chemotherapy; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Cost-effectiveness of new oral anticoagulants in the prevention of stroke in patients with atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Drug Administration Schedule; Humans; Intracranial Hemorrhages; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Warfarin | 2013 |
Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; Contraindications; Coronary Artery Bypass; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Secondary Prevention; Stents; Stroke; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine | 2013 |
Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis.
Topics: Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Recurrence; Rivaroxaban; Thiophenes; Venous Thromboembolism; Vitamin K | 2013 |
[Oral antiplatelet agents can still be used along with proton pump inhibitors in spite of drug interactions].
Topics: Adenosine; Administration, Oral; Aspirin; Clopidogrel; Cyclooxygenase Inhibitors; Drug Interactions; Drug Therapy, Combination; Gastrointestinal Hemorrhage; Humans; Piperazines; Prasugrel Hydrochloride; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Factors; Thienopyridines; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
[Thrombocyte aggregation inhibitors: what are the risks?].
Topics: Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Interactions; Drug Resistance; Drug Therapy, Combination; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Stents; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Anticoagulant and antiplatelet medications encountered in emergency surgery patients: a review of reversal strategies.
Topics: Anticoagulants; Aspirin; Benzimidazoles; Clopidogrel; Dabigatran; Emergencies; Enoxaparin; Fondaparinux; Heparin; Humans; Morpholines; Platelet Aggregation Inhibitors; Platelet Transfusion; Polysaccharides; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Surgical Procedures, Operative; Thiophenes; Ticlopidine; Warfarin | 2013 |
Use of antiplatelet agents in patients with atherosclerotic disease.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Atherosclerosis; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
The risk of recurrent thromboembolic disorders in patients with unprovoked venous thromboembolism: new scenarios and opportunities.
Topics: Age Factors; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Dabigatran; Disease Management; Female; Fibrin Fibrinogen Degradation Products; Fibrinolytic Agents; Fondaparinux; Humans; Male; Morpholines; Obesity; Polysaccharides; Postthrombotic Syndrome; Pulmonary Embolism; Risk Assessment; Risk Factors; Rivaroxaban; Secondary Prevention; Sex Factors; Thiophenes; Thrombophilia; Ultrasonography; Venous Thromboembolism; Venous Thrombosis; Warfarin | 2014 |
Dual antiplatelet therapy -- management in general practice.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Antiplatelet treatment for prevention of cerebrovascular events in patients with vascular diseases: a systematic review and meta-analysis.
Topics: Adenosine; Aged; Aspirin; Cerebral Hemorrhage; Cerebrovascular Disorders; Clopidogrel; Cohort Studies; Data Interpretation, Statistical; Drug Therapy, Combination; Female; Humans; Ischemic Attack, Transient; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Population; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Purinergic P2; Secondary Prevention; Stroke; Thiophenes; Ticagrelor; Ticlopidine; Vascular Diseases | 2014 |
[Differentiated antiplatelet therapy for acute coronary syndromes].
Topics: Acute Coronary Syndrome; Adenosine; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Platelet Transfusion; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Anticoagulation and antiplatelet therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Enoxaparin; Fondaparinux; Heparin; Hirudins; Humans; Morpholines; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Recombinant Proteins; Rivaroxaban; Thiophenes; Ticagrelor; Ticlopidine; Warfarin | 2014 |
Unanswered questions in patients with concurrent atrial fibrillation and acute coronary syndrome.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Comorbidity; Drug Therapy, Combination; Factor Xa Inhibitors; Humans; Morpholines; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Thrombosis; Ticlopidine | 2014 |
Optimal aspirin dose in acute coronary syndromes: an emerging consensus.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Dose-Response Relationship, Drug; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Thiophenes; Ticagrelor | 2014 |
[Using ADP receptor antagonists in coronary heart disease and acute coronary syndrome].
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Early Medical Intervention; General Practice; Guideline Adherence; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Stents; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Management of acute coronary syndrome in the hospital: a focus on ACCF/AHA guideline updates to oral antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aspirin; Body Weight; Clopidogrel; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Quality of Health Care; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold?
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Anticoagulants; Aspirin; Drug Therapy, Combination; Enoxaparin; Eptifibatide; Fondaparinux; Heparin; Hirudins; Humans; Lactones; Peptide Fragments; Peptides; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Pyridines; Receptors, Thrombin; Recombinant Proteins; Thiophenes; Ticagrelor; Tirofiban; Tyrosine; Warfarin | 2014 |
[More with atrial fibrillation, anticoagulants since the coming of NOAK ].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; Drug Prescriptions; Drug Utilization; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Thiophenes; Warfarin | 2015 |
Prasugrel hydrochloride for the treatment of acute coronary syndromes.
Topics: Acute Coronary Syndrome; Animals; Aspirin; Clinical Trials, Phase III as Topic; Clopidogrel; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine | 2015 |
[Anticoagulant therapy in secondary prevention of coronary events].
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Clopidogrel; Dabigatran; Hemorrhage; Humans; Morpholines; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Secondary Prevention; Thiophenes; Ticlopidine; Warfarin | 2014 |
Clinical evidence for oral antiplatelet therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combination; Humans; Intraoperative Care; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Thiophenes; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Platelets in patients with aspirin-exacerbated respiratory disease.
Topics: Animals; Aspirin; Asthma, Aspirin-Induced; Blood Platelets; Bridged Bicyclo Compounds, Heterocyclic; Cell Movement; Clinical Trials as Topic; Eosinophils; Gene Expression; Humans; Leukotrienes; Oxazoles; Piperazines; Platelet Activating Factor; Platelet Activation; Prasugrel Hydrochloride; Receptors, Leukotriene; Thiophenes; Thromboxane A2 | 2015 |
65 trial(s) available for aspirin and thiophenes
| Article | Year |
|---|---|
Protective effect of ketotifen and disodium cromoglycate against bronchoconstriction induced by aspirin, benzoic acid or tartrazine in intolerant asthmatics.
Topics: Adult; Aged; alpha 1-Antitrypsin; Aspirin; Asthma; Benzoates; Bronchial Spasm; Complement C1 Inactivator Proteins; Cromolyn Sodium; Female; Forced Expiratory Volume; Humans; Male; Middle Aged; Piperidines; Tartrazine; Thiophenes | 1979 |
[Platelet function inhibitors in peripheral arteriopathies].
Topics: Adrenal Cortex Hormones; Adrenergic alpha-Antagonists; Anti-Inflammatory Agents; Arachidonic Acid; Arachidonic Acids; Arteriosclerosis Obliterans; Aspirin; Blood Platelets; Calcium Channel Blockers; Clinical Trials as Topic; Cyclic AMP; Dipyridamole; Extremities; Heparin; Humans; Imidazoles; Prostaglandins; Prostanoic Acids; Pyrazoles; Pyrazolones; Quinacrine; Thiophenes; Thromboembolism; Thrombosis; Ticlopidine; Vascular Diseases | 1986 |
Preserved renal perfusion during beta blockade by tertatolol with and without cyclooxygenase inhibition in normal humans.
Topics: Adult; Aspirin; Blood Pressure; Cardiac Output; Cyclooxygenase Inhibitors; Double-Blind Method; Drug Interactions; Glomerular Filtration Rate; Heart Rate; Humans; Male; Perfusion; Propanolamines; Random Allocation; Renal Circulation; Thiophenes | 1988 |
Clinical trials evaluating platelet-modifying drugs in patients with atherosclerotic cardiovascular disease and thrombosis.
Topics: Anticoagulants; Aspirin; Blood Platelets; Blood Vessel Prosthesis; Cardiovascular Diseases; Clinical Trials as Topic; Dipyridamole; Double-Blind Method; Female; Glomerulonephritis; Graft Occlusion, Vascular; Heart Valve Prosthesis; Humans; Ischemic Attack, Transient; Male; Myocardial Infarction; Postoperative Complications; Random Allocation; Sulfinpyrazone; Thiophenes; Ticlopidine | 1986 |
Controlled trial of desmopressin in liver cirrhosis and other conditions associated with a prolonged bleeding time.
Topics: Adolescent; Adult; Aged; Aspirin; Bleeding Time; Clinical Trials as Topic; Deamino Arginine Vasopressin; Female; Humans; Liver Cirrhosis; Male; Middle Aged; Platelet Count; Platelet Function Tests; Random Allocation; Thiophenes; Thrombocytopenia; Ticlopidine; von Willebrand Factor | 1986 |
Evaluation of antiplatelet agents in the prevention of aorto-coronary bypass occlusion.
Topics: Administration, Oral; Anticoagulants; Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Artery Bypass; Coronary Disease; Dipyridamole; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fibrinolytic Agents; Graft Occlusion, Vascular; Heparin; Humans; Platelet Aggregation; Saphenous Vein; Sulfinpyrazone; Thiophenes; Ticlopidine | 1986 |
[Aftercare of heart infarct patients to reduce the risk of a subsequent infarction].
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Clinical Trials as Topic; Dipyridamole; Humans; Hypolipidemic Agents; Myocardial Infarction; Patient Care Planning; Platelet Aggregation; Recurrence; Risk; Sulfinpyrazone; Thiophenes; Ticlopidine | 1983 |
The North American ticlopidine aspirin stroke study: structure, stratification variables, and patient characteristics.
Topics: Age Factors; Aged; Anticoagulants; Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Random Allocation; Thiophenes; Ticlopidine | 1984 |
The effect of ticlopidine on TIA compared with aspirin: a double-blind, twelve-month follow-up study.
Topics: Anticoagulants; Aspirin; Clinical Trials as Topic; Double-Blind Method; Follow-Up Studies; Humans; Ischemic Attack, Transient; Thiophenes; Ticlopidine | 1984 |
Registry of prospective clinical trials--fifth report.
Topics: Aspirin; Clinical Trials as Topic; Coronary Artery Bypass; Coronary Disease; Dipyridamole; Double-Blind Method; Heart Valve Prosthesis; Heparin; Humans; Intermittent Claudication; Myocardial Infarction; Prospective Studies; Registries; Thiophenes; Thromboembolism; Thrombophlebitis; Thrombosis; Ticlopidine | 1982 |
A comparative double-blind study of tiaprofenic acid and aspirin in the treatment of muscular rheumatism, fibrositis, sprains and soft tissue injuries in general practice.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Double-Blind Method; Female; Fibromyalgia; Humans; Male; Middle Aged; Pain; Propionates; Sprains and Strains; Thiophenes; Wounds and Injuries | 1980 |
[On the pharmacokinetics of tiaprofenic acid and its possible interactions with acetylsalicylic acid and aluminum hydroxide (author's transl)].
Topics: Aluminum Hydroxide; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biological Availability; Drug Interactions; Humans; Kinetics; Male; Propionates; Thiophenes | 1981 |
The comparative effectiveness of tiaprofenic acid and aspirin in the treatment of post-prostatectomy pain.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Humans; Male; Middle Aged; Pain, Postoperative; Propionates; Prostatectomy; Thiophenes; Wound Healing | 1981 |
A comparative trial of tiaprofenic acid ('Surgam') versus aspirin in the control of pain following injury.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Male; Middle Aged; Pain; Propionates; Thiophenes; Wounds and Injuries | 1981 |
Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease.
Topics: Adult; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2006 |
Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban--an oral, direct factor Xa inhibitor--are not affected by aspirin.
Topics: Administration, Oral; Adolescent; Adult; Antithrombin III; Aspirin; Bleeding Time; Dose-Response Relationship, Drug; Drug Tolerance; Humans; Male; Middle Aged; Molecular Structure; Morpholines; Platelet Aggregation; Rivaroxaban; Thiophenes | 2006 |
Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects.
Topics: Adenosine Diphosphate; Adolescent; Adult; Aspirin; Bleeding Time; Clopidogrel; Collagen; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Male; Middle Aged; Peptide Fragments; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Purinergic P2 Receptor Antagonists; Stroke; Thiophenes; Thrombosis; Ticlopidine | 2007 |
Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease.
Topics: Adult; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Treatment Outcome | 2008 |
The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration.
Topics: Adult; Aspirin; Blood Coagulation Tests; Blood Platelets; Clopidogrel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Point-of-Care Systems; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Reference Values; Reproducibility of Results; Thiophenes; Ticlopidine | 2008 |
Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolys
Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Drug Therapy, Combination; Hemorrhage; Humans; Kaplan-Meier Estimate; Myocardial Infarction; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Purinergic P2 Receptor Antagonists; Stents; Thiophenes; Ticlopidine | 2008 |
Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects.
Topics: Adenosine Diphosphate; Adult; Aspirin; Clopidogrel; Drug-Related Side Effects and Adverse Reactions; Female; Hemorrhage; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2008 |
Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease.
Topics: Adult; Aspirin; Biomarkers; Blood Platelets; Cell Communication; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Monocytes; P-Selectin; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2008 |
Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Models, Biological; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2008 |
Assessment of P2Y(12) inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin.
Topics: Anticoagulants; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Male; Optical Rotation; Phosphorylation; Piperazines; Point-of-Care Systems; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Method; Endpoint Determination; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2009 |
Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease.
Topics: Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Disease; Cytochrome P-450 CYP2C19; Drug Interactions; Female; Genetic Variation; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2009 |
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.
Topics: Acute Coronary Syndrome; Administration, Oral; Aspirin; Chest Pain; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Morpholines; Myocardial Infarction; Proportional Hazards Models; Pyridines; Recurrence; Risk Reduction Behavior; Rivaroxaban; Safety; Statistics, Nonparametric; Stroke; Thiophenes; Treatment Outcome | 2009 |
Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitio
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2009 |
Effect of age on the pharmacokinetics and pharmacodynamics of prasugrel during multiple dosing: an open-label, single-sequence, clinical trial.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Aging; Aspirin; Bleeding Time; Body Mass Index; Confidence Intervals; Drug Therapy, Combination; Fasting; Female; Humans; Least-Squares Analysis; Male; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Purinergic P2 Receptor Antagonists; Statistics, Nonparametric; Tablets, Enteric-Coated; Thiophenes; Young Adult | 2009 |
Reducing cardiac ischemic events in patients with ACS: prasugrel versus clopidogrel. Commentary.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Confidence Intervals; Double-Blind Method; Drug Therapy, Combination; Humans; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Thiophenes; Ticlopidine | 2010 |
Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance--the BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy.
Topics: Aspirin; Clopidogrel; Demography; Drug Resistance; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Receptors, Purinergic P2; Risk Factors; Thiophenes; Ticlopidine | 2011 |
A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial.
Topics: Adolescent; Adult; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Thiophenes; Ticlopidine; Treatment Outcome; Young Adult | 2011 |
Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel--Thrombolysis in Myocardial Infarction 38 (TRITON-
Topics: Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Predictive Value of Tests; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Thrombolytic Therapy; Ticlopidine | 2011 |
Pharmacodynamic assessment of a novel P2Y12 receptor antagonist in Japanese patients with coronary artery disease undergoing elective percutaneous coronary intervention.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Female; Humans; Japan; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Young Adult | 2012 |
Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Drug Interactions; Enoxaparin; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Platelet Aggregation Inhibitors; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2012 |
Effects on platelet function of a direct acting antagonist of coagulation factor Xa.
Topics: Adenosine Monophosphate; Aged; Anticoagulants; Aspirin; Blood Platelets; Coronary Artery Disease; Crotalid Venoms; Factor Xa; Factor Xa Inhibitors; Female; Humans; Lectins, C-Type; Male; Middle Aged; Morpholines; Plant Proteins; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Rivaroxaban; Thiophenes | 2012 |
Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Loss, Surgical; Cause of Death; Chest Tubes; Clopidogrel; Cohort Studies; Combined Modality Therapy; Coronary Artery Bypass; Drug Administration Schedule; Drug Therapy, Combination; Erythrocyte Transfusion; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Recurrence; Retrospective Studies; Risk Adjustment; Thiophenes; Ticlopidine | 2012 |
Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial.
Topics: Adult; Aged; Aspirin; Blood Loss, Surgical; Blood Platelets; Clopidogrel; Confounding Factors, Epidemiologic; Coronary Disease; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2012 |
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Cardiovascular Diseases; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Stroke; Thiophenes; Ticlopidine | 2012 |
Randomized comparison of new dual-antiplatelet therapy (aspirin, prasugrel) and triple-antiplatelet therapy (aspirin, clopidogrel, cilostazol) using P2Y12 point-of-care assay in patients with STEMI undergoing primary PCI.
Topics: Adult; Aged; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Point-of-Care Systems; Prasugrel Hydrochloride; Prospective Studies; Receptors, Purinergic P2Y12; Tetrazoles; Thiophenes; Ticlopidine | 2013 |
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Angina, Unstable; Aspirin; Body Weight; Clopidogrel; Female; Humans; Male; Myocardial Infarction; Myocardial Ischemia; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Stroke; Thiophenes; Ticlopidine; Treatment Outcome | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Point-of-Care Systems; Prasugrel Hydrochloride; Pyridines; Retreatment; Stents; Thiophenes; Ticlopidine | 2012 |
Platelet function normalization after a prasugrel loading-dose: time-dependent effect of platelet supplementation.
Topics: Acute Coronary Syndrome; Adult; Aspirin; Biotransformation; Blood Platelets; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hemostasis; Humans; Male; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Transfusion; Prasugrel Hydrochloride; Prospective Studies; Thiophenes | 2013 |
ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatm
Topics: Absorbable Implants; Adult; Aged; Aspirin; Coronary Angiography; Coronary Artery Disease; Coronary Thrombosis; Drug-Eluting Stents; Europe; Everolimus; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Myocardial Ischemia; New Zealand; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Research Design; Sample Size; Single-Blind Method; Sirolimus; Spectroscopy, Near-Infrared; Thiophenes; Tissue Scaffolds; Tomography, X-Ray Computed; Ultrasonography, Interventional | 2012 |
The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study.
Topics: Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Smoking; Thiophenes; Ticlopidine | 2013 |
Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Morpholines; Platelet Aggregation Inhibitors; Pyridines; Rivaroxaban; Stents; Thiophenes; Thrombosis; Treatment Outcome | 2013 |
Open-label, randomized study of the effect of rivaroxaban with or without acetylsalicylic acid on thrombus formation in a perfusion chamber.
Topics: Adolescent; Adult; Animals; Anticoagulants; Aspirin; Cross-Over Studies; Female; Humans; In Vitro Techniques; Male; Middle Aged; Morpholines; Platelet Aggregation; Rivaroxaban; Swine; Thiophenes; Thrombosis; Venous Thromboembolism; Young Adult | 2013 |
Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Disease Management; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hemorrhage; Humans; Longitudinal Studies; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Ticlopidine; Treatment Outcome | 2013 |
Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Data Interpretation, Statistical; Databases, Bibliographic; Double-Blind Method; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Embolism; Female; Humans; Kaplan-Meier Estimate; Male; Morpholines; Myocardial Infarction; Platelet Aggregation Inhibitors; Pyridines; Rivaroxaban; Stroke; Thiophenes; Ticlopidine; Treatment Outcome; Warfarin | 2014 |
Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibit
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Patient Discharge; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome | 2014 |
Pharmacodynamic effects of standard dose prasugrel versus high dose clopidogrel in non-diabetic obese patients with coronary artery disease.
Topics: Aspirin; Biomarkers; Blood Platelets; Body Mass Index; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Florida; Humans; Male; Microfilament Proteins; Middle Aged; Obesity; Phosphoproteins; Phosphorylation; Piperazines; Platelet Activation; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome | 2014 |
Detecting a thienopyridine effect by platelet reactivity assessment and its implications for risk stratification.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Piperazines; Platelet Activation; Point-of-Care Systems; Prasugrel Hydrochloride; Pyridines; Receptors, Purinergic P2Y12; Reproducibility of Results; ROC Curve; Sensitivity and Specificity; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome | 2014 |
A comparative evaluation of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Adult; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Treatment Outcome | 2013 |
Administering aspirin, rivaroxaban and low-molecular-weight heparin to prevent deep venous thrombosis after total knee arthroplasty.
Topics: Aged; Aged, 80 and over; Arthroplasty, Replacement, Knee; Aspirin; Female; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Morpholines; Prospective Studies; Rivaroxaban; Thiophenes; Venous Thrombosis | 2014 |
Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Asian People; Aspirin; Clopidogrel; Drug Therapy, Combination; Follow-Up Studies; Hemorrhage; Humans; Japan; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Time Factors | 2014 |
Impact of point-of-care testing for CYP2C19 on platelet inhibition in patients with acute coronary syndrome and early dual antiplatelet therapy in the emergency setting.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Cytochrome P-450 CYP2C19; Female; Humans; Male; Pilot Projects; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Point-of-Care Systems; Prasugrel Hydrochloride; Thiophenes; Ticagrelor | 2014 |
Comparison of double (360 mg) ticagrelor loading dose with standard (60 mg) prasugrel loading dose in ST-elevation myocardial infarction patients: the Rapid Activity of Platelet Inhibitor Drugs (RAPID) primary PCI 2 study.
Topics: Adenosine; Aged; Aspirin; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Premedication; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Time Factors; Treatment Outcome | 2014 |
Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y12 inhibition: Results of the randomized DOSAPI study.
Topics: Adult; Aged; Anti-Ulcer Agents; Aspirin; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Drug Interactions; Female; Humans; Lansoprazole; Male; Middle Aged; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine | 2014 |
An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Cohort Studies; Coronary Artery Bypass; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Stents; Stroke; Thiophenes; Ticlopidine | 2014 |
Antithrombotic triple therapy and coagulation activation at the site of thrombus formation: a randomized trial in healthy subjects.
Topics: Adenosine; Administration, Oral; Adult; Anticoagulants; Antithrombin III; Aspirin; Austria; Benzimidazoles; beta-Alanine; beta-Thromboglobulin; Biomarkers; Blood Coagulation; Blood Platelets; Dabigatran; Drug Therapy, Combination; Fibrinolytic Agents; Healthy Volunteers; Humans; International Normalized Ratio; Male; Morpholines; Peptide Fragments; Peptide Hydrolases; Phenprocoumon; Platelet Activation; Platelet Aggregation Inhibitors; Prospective Studies; Prothrombin; Rivaroxaban; Thiophenes; Thrombin; Thrombosis; Ticagrelor; Young Adult | 2014 |
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
Topics: Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombosis; Ticlopidine; Time Factors | 2014 |
Prasugrel plus aspirin beyond 12 months is associated with improved outcomes after TAXUS Liberté paclitaxel-eluting coronary stent placement.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Incidence; Internationality; Male; Middle Aged; Myocardial Infarction; Paclitaxel; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Pyridines; Thiophenes; Time Factors; Treatment Outcome | 2015 |
Long-term efficacy and safety of biodegradable-polymer biolimus-eluting stents: main results of the Basel Stent Kosten-Effektivitäts Trial-PROspective Validation Examination II (BASKET-PROVE II), a randomized, controlled noninferiority 2-year outcome tria
Topics: Absorbable Implants; Aged; Anti-Inflammatory Agents; Aspirin; Coronary Artery Disease; Drug-Eluting Stents; Everolimus; Female; Humans; Kaplan-Meier Estimate; Longitudinal Studies; Male; Metals; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Polymers; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Single-Blind Method; Sirolimus; Stents; Switzerland; Thiophenes; Treatment Outcome | 2015 |
147 other study(ies) available for aspirin and thiophenes
| Article | Year |
|---|---|
Prediction of drug solubility from Monte Carlo simulations.
Topics: Monte Carlo Method; Pharmaceutical Preparations; Solubility | 2000 |
Antagonism of arachidonic acid hydroperoxide on isolated gastrointestinal tissues as a measure of the inhibition of prostaglandin biosynthesis.
Topics: Angiotensin II; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acids; Aspirin; Biological Assay; Bradykinin; Depression, Chemical; Dose-Response Relationship, Drug; Guinea Pigs; Histamine H1 Antagonists; In Vitro Techniques; Indomethacin; Muscle Contraction; Muscle, Smooth; Peroxides; Phenylbutazone; Phenylpropionates; Prostaglandin Antagonists; Prostaglandins; Prostaglandins E; Prostaglandins F; Rats; Serotonin Antagonists; Thiophenes | 1976 |
The protective effect of a new oral anti-asthma agent (ketotifen, HC 20--511) against experimentally induced bronchospasm (5 different models).
Topics: Acetylcholine; Aerosols; Antigens; Aspirin; Benzoates; Bronchial Spasm; Double-Blind Method; Histamine; Histamine H1 Antagonists; Humans; Physical Exertion; Piperidines; Placebos; Tartrazine; Thiophenes | 1978 |
[Kinetics of I-131 fibrinogen in cancer patients: pharmacological approach].
Topics: Aspirin; Blood Coagulation; Fibrinogen; Fibrinolytic Agents; Heparin; Indomethacin; Iodine Radioisotopes; Kinetics; Neoplasms; Platelet Aggregation; Prednisone; Pyridines; Thiophenes | 1977 |
Mode of action of ticlopidine in inhibition of platelet aggregation in the rat.
Topics: Adenylyl Cyclases; Animals; Aspirin; Blood Platelets; Cell Membrane; Cyclic AMP; Dose-Response Relationship, Drug; Kinetics; Male; Phosphoric Diester Hydrolases; Platelet Aggregation; Prostaglandins; Prostaglandins E; Pyridines; Rats; Thiophenes | 1979 |
Evaluation of antiinflammatory and antithrombotic drugs in pulmonary and arterial thrombosis.
Topics: 2',3'-Cyclic-Nucleotide Phosphodiesterases; Animals; Anti-Inflammatory Agents; Arterial Occlusive Diseases; Aspirin; Benzophenones; Carotid Arteries; Cattle; Dipyridamole; Drug Evaluation; Fibrinolytic Agents; Humans; Imidazoles; Indoles; Indomethacin; Lung Diseases, Obstructive; Male; Mice; Platelet Aggregation; Prostaglandins; Pyridines; Quinazolines; Rats; Sulfinpyrazone; Sulfonamides; Suloctidil; Thiophenes | 1979 |
Effect of ticlopidine and acetylsalicylic acid on generation of prostaglandin I2-like substance in rat arterial tissue.
Topics: Animals; Aspirin; Carotid Arteries; Epoprostenol; Male; Platelet Aggregation; Prostaglandins; Pyridines; Rats; Thiophenes; Tissue Extracts | 1978 |
The interactions of ticlopidine and aspirin in normal subjects.
Topics: Adult; Aspirin; Drug Synergism; Female; Humans; Male; Middle Aged; Platelet Aggregation; Pyridines; Thiophenes | 1977 |
Effects of suprofen, an inhibitor of prostaglandin biosynthesis, on platelet function, plasma coagulation and fibrinolysis II. In vivo experiments.
Topics: Adenosine Diphosphate; Animals; Aspirin; Blood Coagulation; Blood Platelets; Collagen; Dogs; Fibrinolysis; Guinea Pigs; Hemostasis; Male; Phenylbutazone; Phenylpropionates; Platelet Adhesiveness; Platelet Aggregation; Prostaglandin Antagonists; Pyrimidines; Rats; Thiophenes; Time Factors; Warfarin | 1975 |
Suprofen, a potent antagonist of acetic acid-induced writhing in rats.
Topics: Acetates; Analgesics; Animals; Arachidonic Acids; Aspirin; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Indomethacin; Ketoprofen; Male; Muscle Contraction; Phenylacetates; Phenylbutazone; Phenylpropionates; Prostaglandin Antagonists; Prostaglandins; Rats; Spasm; Thiophenes; Tolmetin | 1975 |
Suprofen, a potent antagonist of sodium urate crystal-induced arthritis in dogs.
Topics: Animals; Anti-Inflammatory Agents; Arthritis; Aspirin; Dogs; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Indomethacin; Knee Joint; Male; Phenylbutazone; Phenylpropionates; Thiophenes; Time Factors; Uric Acid | 1975 |
The activity of suprofen on nystatin-induced paw oedema in rats.
Topics: Animals; Anti-Inflammatory Agents; Aspirin; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Edema; Hindlimb; Indomethacin; Male; Nystatin; Phenylbutazone; Phenylpropionates; Rats; Thiophenes; Time Factors | 1975 |
The antipyretic effect of suprofen in rats with yeast-induced fever.
Topics: Analgesics; Animals; Aspirin; Body Temperature; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Fever; Indomethacin; Male; Phenylbutazone; Phenylpropionates; Rats; Thiophenes; Time Factors; Tolmetin; Yeast, Dried | 1975 |
The effects of suprofen in rats with Mycobacterium butyricum-induced arthritis.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Biometry; Body Weight; Bone and Bones; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation, Preclinical; Haptoglobins; Hindlimb; Indomethacin; Phenylbutazone; Phenylpropionates; Rats; Tarsal Joints; Thiophenes; Tolmetin | 1975 |
Gastrointestinal effects and acute toxicity of suprofen.
Topics: Animals; Antidiarrheals; Aspirin; Digestive System; Dogs; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Eating; Female; Guinea Pigs; Indomethacin; Ketoprofen; Lethal Dose 50; Male; Mice; Phenylacetates; Phenylpropionates; Rats; Rats, Inbred Strains; Thiophenes; Time Factors; Ulcer | 1975 |
Individual and combined effects of a thromboxane receptor antagonist and different antithrombotic agents in a rat microcirculatory thrombosis model.
Topics: Animals; Aspirin; Drug Synergism; Epoprostenol; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Lasers; Lysine; Male; Microcirculation; Molsidomine; Rats; Rats, Wistar; Receptors, Thromboxane; Sulfonamides; Thiophenes; Thrombophlebitis; Venules | 1992 |
Evaluation of 2-(2-thiophenecarboxy)benzoic acid and related active metabolites in biological samples.
Topics: Animals; Aspirin; Benzoates; Chromatography, Liquid; Female; Hydrogen-Ion Concentration; Male; Naproxen; Rats; Rats, Inbred Strains; Salicylates; Salicylic Acid; Spectrophotometry, Ultraviolet; Thiophenes; Tissue Distribution | 1992 |
Standardization of the rat paw formalin test for the evaluation of analgesics.
Topics: Analgesics; Animals; Aspirin; Behavior, Animal; Decerebrate State; Foot; Formaldehyde; Male; Morphine; Pain; Pyrroles; Rats; Rats, Inbred Strains; Reference Standards; Thiophenes | 1991 |
In vitro antiplatelet profiles of the new thromboxane synthetase inhibitor sodium 2-(1-imidazolylmethyl)-4,5-dihydrobenzo[b]thiophene-6-carboxylate.
Topics: 6-Ketoprostaglandin F1 alpha; Adult; Animals; Aspirin; Dogs; Humans; Imidazoles; In Vitro Techniques; Male; Methacrylates; Platelet Aggregation; Platelet Aggregation Inhibitors; Rabbits; Thiophenes; Thromboxane B2; Thromboxane-A Synthase; Thromboxanes | 1991 |
Phototoxicity of non-steroidal anti-inflammatory drugs demonstrated in vitro by a photo-basophil-histamine-release test.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Basophils; Carbazoles; Diclofenac; Histamine Release; Humans; In Vitro Techniques; Indoprofen; Ketoprofen; Leukocytes; Photosensitivity Disorders; Propionates; Thiophenes; Ultraviolet Rays | 1987 |
Hemostatic effects of microfibrillar collagen hemostat (MCH) in experimental coagulopathy model and its mechanism of hemostasis.
Topics: Animals; Aspirin; Blood Coagulation Disorders; Cattle; Collagen; Dogs; Hemorrhage; Hemostatic Techniques; Hemostatics; Heparin; Spleen; Thiophenes; Thrombocytopenia; Ticlopidine; Warfarin | 1986 |
Ticlopidine versus aspirin and dipyridamole: influence on platelet deposition and three-month patency of polytetrafluoroethylene grafts.
Topics: Animals; Anticoagulants; Aspirin; Blood Vessel Prosthesis; Dipyridamole; Dogs; Female; Femoral Artery; Graft Occlusion, Vascular; Indium; Male; Platelet Aggregation; Polytetrafluoroethylene; Radioisotopes; Thiophenes; Ticlopidine | 1986 |
[Prevention and medical treatment of polyregional vascular lesions].
Topics: Adult; Anticoagulants; Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Diet; Dipyridamole; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Risk; Sulfinpyrazone; Thiophenes; Thrombosis; Ticlopidine | 1985 |
[Activity of ticlopidine and lysine acetylsalicylate in experimental atheromatosis. Effects on the production of PGI2].
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Aorta; Arteriosclerosis; Aspirin; Diet, Atherogenic; Epoprostenol; Lysine; Male; Platelet Aggregation; Rabbits; Thiophenes; Ticlopidine | 1985 |
Antiplatelet aggregators inhibit development of stress ulcers in Sprague-Dawley rats.
Topics: Animals; Anticoagulants; Aspirin; Capillaries; Dipyridamole; Gastric Mucosa; Male; Platelet Aggregation; Pyridines; Rats; Rats, Inbred Strains; Stomach Ulcer; Stress, Physiological; Sulfinpyrazone; Thiophenes; Thrombosis; Ticlopidine | 1985 |
Antithrombotic effect of ticlopidine in a platelet-independent model of venous thrombosis.
Topics: Animals; Aspirin; Blood Platelets; Fibrinolytic Agents; Male; Rats; Rats, Inbred Strains; Thiophenes; Thrombophlebitis; Ticlopidine | 1985 |
[Studies on anti-inflammatory agents. 18. Effect of 2-amino-3-ethoxycarbonyl-6-benzyl-4,5,6,7-tetrahydrothieno(2,3-c)pyridine (Y-3642) on the release of histamine in vitro and in vivo].
Topics: Animals; Anti-Inflammatory Agents; Aspirin; Benzyl Compounds; Depression, Chemical; Dextrans; Diphenhydramine; Flufenamic Acid; Histamine Release; In Vitro Techniques; Mast Cells; Phenylbutazone; Polymyxins; Pyridines; Rats; Thiophenes; Thromboplastin | 1971 |
[Studies on anti-inflammatory agents. XVII. Effects of 2-amino-3-ethoyxycarbonyl-6-benzyl-4,5,6,7-tetrahydrothieno(2,3-c)pyridine (Y-3642) hydrochoride on oxidative phosphorylation, swelling and adenosine triphosphatase of rat liver mitochondria].
Topics: Adenosine Triphosphatases; Animals; Anti-Inflammatory Agents; Aspirin; Depression, Chemical; In Vitro Techniques; Indomethacin; Male; Mitochondria, Liver; Mitochondrial Swelling; Oxidative Phosphorylation; Phenylacetates; Phenylbutazone; Pyridines; Rats; Stimulation, Chemical; Thiophenes | 1971 |
[The continuous measurement of platelet aggregation without the addition of aggregation inducers. II. Experimental results and testing of aggregation inducers].
Topics: Aspirin; Benzyl Compounds; Cycloheptanes; Dimethylamines; Ethanolamines; Fibrinogen; Humans; In Vitro Techniques; Morpholines; Photometry; Piperazines; Piperidines; Platelet Adhesiveness; Platelet Aggregation; Polysaccharides; Pyrimidines; Sulfuric Acids; Thiophenes | 1974 |
The prevention of endotoxin-induced glomerular fibrin deposition by pyrimido-pyrimidine compounds.
Topics: Animals; Aspirin; Blood Cell Count; Blood Platelets; Disseminated Intravascular Coagulation; Endotoxins; Escherichia coli; Female; Fibrin; Fibrinogen; Injections, Intravenous; Kidney Glomerulus; Microcirculation; Morpholines; Pyrimidines; Rabbits; Thiophenes | 1972 |
Effects of some narcotic analgesics and related compounds upon the extensor monosynaptic reflex inhibition from cutaneous nerve and high threshold muscle afferents.
Topics: Amines; Analgesics; Animals; Aspirin; Bridged-Ring Compounds; Cats; Citrates; Depression, Chemical; Fentanyl; Heterocyclic Compounds; Levallorphan; Morphine; Muscles; Nalorphine; Narcotics; Neurons, Afferent; Pentazocine; Reflex, Monosynaptic; Skin; Spinal Cord; Thebaine; Thiophenes | 1971 |
Inhibition by ketotifen of idiosyncratic reactions to aspirin.
Topics: Adult; Aspirin; Asthma; Bronchi; Bronchial Spasm; Drug Hypersensitivity; Female; Histamine H1 Antagonists; Humans; Ketotifen; Male; Middle Aged; Piperidines; Placebos; Thiophenes | 1980 |
Laser-induced thrombi in rat mesenteric vessels and antithrombotic drugs.
Topics: Animals; Aspirin; Blood Platelets; Dipyridamole; Disease Models, Animal; Fibrinolytic Agents; Heparin; Lasers; Male; Mesenteric Arteries; Mesenteric Vascular Occlusion; Molsidomine; Oxazoles; Platelet Aggregation; Propionates; Pyrazoles; Pyrazolones; Rats; Rats, Inbred Strains; Sydnones; Thiophenes; Thrombosis; Ticlopidine | 1983 |
The thrombogenicity of Dacron arterial grafts and its modification by platelet inhibitory drugs.
Topics: Arteries; Aspirin; Blood Platelets; Blood Vessel Prosthesis; Dipyridamole; Drug Therapy, Combination; Humans; Microscopy, Electron; Platelet Adhesiveness; Platelet Aggregation; Polyethylene Terephthalates; Sulfinpyrazone; Thiophenes; Thrombosis; Ticlopidine | 1984 |
[The effect of ticlopidine and lysine acetylsalicylate on fibrinolytic activity of the arterial wall in experimental atherosclerosis].
Topics: Animals; Arteriosclerosis; Aspirin; Fibrinolysis; Lysine; Male; Muscle, Smooth, Vascular; Rabbits; Thiophenes; Ticlopidine | 1984 |
Inhibition of thrombocytopenic episodes caused by the Arthus reaction, the sub-lethal Forssman reaction and ADP.
Topics: Adenosine Diphosphate; Animals; Antibodies; Arthus Reaction; Aspirin; Dipyridamole; Forssman Antigen; Guinea Pigs; Humans; Nervous System Diseases; Platelet Count; Pyridines; Sulfides; Sulfinpyrazone; Thiophenes; Thrombocytopenia; Ticlopidine | 1980 |
Effects of various antiplatelet drugs and defibrinating agent on experimental glomerulonephritis in rats.
Topics: Animals; Anticoagulants; Aspirin; Batroxobin; Blood Platelets; Dipyridamole; Glomerulonephritis; Immune Complex Diseases; Kidney; Nephritis; Proteinuria; Pyridines; Rats; Rats, Inbred Strains; Thiophenes; Ticlopidine | 1982 |
In vivo study of platelet aggregation in rats.
Topics: Adenosine Diphosphate; Animals; Aspirin; Collagen; Diet; Dose-Response Relationship, Drug; Male; Methods; Platelet Aggregation; Platelet Count; Rats; Rats, Inbred Strains; Thiophenes; Thrombosis; Ticlopidine | 1984 |
Ex vivo and in vivo evaluation of drugs that inhibit platelet function.
Topics: Adenosine Diphosphate; Animals; Aspirin; Bleeding Time; Blood Platelets; Collagen; Dipyridamole; Imidazoles; Male; Papio; Platelet Aggregation; Sulfinpyrazone; Thiazines; Thiophenes; Ticlopidine | 1983 |
Ticlopidine: quo vadis? Adverse reactions in man.
Topics: Anticoagulants; Aspirin; Diarrhea; Humans; Neutropenia; Product Surveillance, Postmarketing; Thiophenes; Ticlopidine | 1984 |
Thrombotic etiology of stress ulcers. 1. The effect of anticoagulant and antiplatelet aggregators in the development of stress ulcers in rats.
Topics: Animals; Anticoagulants; Aspirin; Dipyridamole; Gastric Acidity Determination; Gastric Mucosa; Heparin; Male; Peptic Ulcer Hemorrhage; Platelet Aggregation; Platelet Count; Rats; Rats, Inbred Strains; Stomach Ulcer; Stress, Physiological; Thiophenes; Thrombosis; Ticlopidine | 1983 |
Effects of ticlopidine and aspirin on endotoxin-induced disseminated intravascular coagulation in rats.
Topics: Animals; Aspirin; Disseminated Intravascular Coagulation; Rats; Thiophenes; Ticlopidine | 1983 |
[Platelet antiaggregants and bleeding time lengthening: management in the preoperative period].
Topics: Adrenal Cortex Hormones; Aspirin; Blood Coagulation; Humans; Platelet Aggregation; Preoperative Care; Thiophenes; Ticlopidine | 1983 |
Antiplatelet drugs and thrombosis prevention: ticlopidine in perspective.
Topics: Adenosine Diphosphate; Aspirin; Bleeding Time; Blood Platelets; Fibrinolytic Agents; Humans; Thiophenes; Thrombosis; Ticlopidine | 1984 |
Platelet aggregation measured in rabbit whole blood: in vitro study of 3 aggregating agents and ex vivo inhibition by aspirin and ticlopidine.
Topics: Adenosine Diphosphate; Animals; Arachidonic Acid; Arachidonic Acids; Aspirin; Collagen; In Vitro Techniques; Platelet Aggregation; Platelet Count; Rabbits; Thiophenes; Ticlopidine | 1982 |
Study of platelet aggregation induced by platelet activating factor (PAF) after administration of ticlopidine or aspirin.
Topics: Adult; Aged; Anticoagulants; Aspirin; Epinephrine; Humans; In Vitro Techniques; Middle Aged; Platelet Activating Factor; Platelet Aggregation; Thiophenes; Ticlopidine | 1983 |
Effects of ticlopidine and aspirin on endotoxin-induced disseminated intravascular coagulation in rats.
Topics: Animals; Aspirin; Disease Models, Animal; Disseminated Intravascular Coagulation; Endotoxins; Female; Fibrin Fibrinogen Degradation Products; Fibrinogen; Kidney Glomerulus; Partial Thromboplastin Time; Platelet Count; Prothrombin Time; Rats; Rats, Inbred Strains; Thiophenes; Ticlopidine | 1983 |
Modulation of the inhibitory action of prostaglandin E1 on platelet aggregation in rats: a study with ticlopidine, aspirin, dipyridamole and sulfinpyrazone.
Topics: Adenosine Diphosphate; Alprostadil; Animals; Aspirin; Dipyridamole; Male; Phosphorylation; Platelet Aggregation; Prostaglandins E; Rats; Rats, Inbred Strains; Sulfinpyrazone; Thiophenes; Ticlopidine | 1982 |
Antithrombotic effects of ticlopidine, acetylsalicyclic acid and dipyridamole in vascular shunt model in rats.
Topics: Animals; Arteriovenous Shunt, Surgical; Aspirin; Blood Coagulation; Blood Coagulation Tests; Dipyridamole; Fibrinogen; Fibrinolytic Agents; Hematocrit; Male; Platelet Aggregation; Platelet Count; Pyridines; Rats; Serum Globulins; Thiophenes; Ticlopidine | 1980 |
Inhibition of idiosyncratic reactions to aspirin by ketotifen.
Topics: Adult; Aspirin; Asthma; Bronchial Spasm; Drug Hypersensitivity; Humans; Ketotifen; Piperidines; Thiophenes | 1980 |
Effect of ticlopidine on human platelet responsiveness ex vivo: comparison with aspirin.
Topics: Adenosine Diphosphate; Adult; Aspirin; Collagen; Dose-Response Relationship, Drug; Epinephrine; Female; Humans; Male; Middle Aged; Platelet Aggregation; Pyridines; Serotonin; Thiophenes; Ticlopidine | 1980 |
Cytoprotective effects of CI-959 in the rat gastric mucosa: modulation of leukocyte adhesion.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Aspirin; Cell Adhesion; Dinoprostone; Dogs; Ethanol; Female; Gastric Acid; Gastric Mucosa; Histamine Antagonists; Indomethacin; Leukocytes; Leukotriene C4; Platelet Activating Factor; Rats; Rats, Sprague-Dawley; Rats, Wistar; Sulfhydryl Compounds; Tetrazoles; Thiophenes | 1995 |
PGHS-2 inhibitors, NS-398 and DuP-697, attenuate the inhibition of PGHS-1 by aspirin and indomethacin without altering its activity.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cattle; Cells, Cultured; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Fibroblasts; Humans; Indomethacin; Isoenzymes; Male; Membrane Proteins; Microsomes; Nitrobenzenes; Prostaglandin-Endoperoxide Synthases; Seminal Vesicles; Sheep; Sulfonamides; Thiophenes | 1999 |
Prostaglandin H synthase-2 inhibitors interfere with prostaglandin H synthase-1 inhibition by nonsteroidal anti-inflammatory drugs.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Aspirin; Cattle; Cyclooxygenase 1; Cyclooxygenase 2; Dinoprostone; Dose-Response Relationship, Drug; Ibuprofen; Indomethacin; Isoenzymes; Male; Microsomes; Nitrobenzenes; Prostaglandin-Endoperoxide Synthases; Seminal Vesicles; Sulfonamides; Thiophenes | 2001 |
Rebound platelet activation after termination of prasugrel and aspirin therapy due to confirmed non-compliance in patient enrolled in the JUMBO Trial.
Topics: Angina Pectoris; Aspirin; Chronic Disease; Coronary Stenosis; Drug Therapy, Combination; Humans; Male; Middle Aged; Myocardial Ischemia; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Treatment Refusal | 2006 |
The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: Influence of other blood cells, calcium, and aspirin.
Topics: Adenosine Diphosphate; Adult; Aspirin; Biomarkers; Blood Cells; Calcium; Cells, Cultured; Female; Humans; Inflammation; Kinetics; Male; Middle Aged; Piperazines; Platelet Activation; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Thrombosis; Up-Regulation | 2007 |
Intensifying platelet inhibition--navigating between Scylla and Charybdis.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemia; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2007 |
Chronic kidney disease--a disease domain complex.
Topics: Aged; Alendronate; Amlodipine; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Aspirin; Bone Density Conservation Agents; Calcium; Diabetes Mellitus, Type 2; Disease Progression; Drug Therapy; Female; Glomerular Filtration Rate; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Kidney Failure, Chronic; Metoprolol; Nitroglycerin; Sulfonamides; Thiophenes | 2008 |
Prasugrel versus clopidogrel.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Humans; Monitoring, Physiologic; Myocardial Infarction; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2008 |
Antiplatelet therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine | 2008 |
Intensive antiplatelet therapy for reduction of ischaemic events.
Topics: Aspirin; Dose-Response Relationship, Drug; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Stents; Thiophenes; Thrombosis | 2008 |
Design and synthesis of 3-pyrazolyl-thiophene, thieno[2,3-d]pyrimidines as new bioactive and pharmacological activities.
Topics: Alternaria; Analgesics; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bacillus cereus; Fusarium; Indomethacin; Microbial Sensitivity Tests; Molecular Structure; Pyrimidines; Salmonella typhi; Structure-Activity Relationship; Thiophenes | 2008 |
Another view on prasugrel.
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Animals; Aspirin; Blood Platelets; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Drug Administration Schedule; Drug Resistance; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Research Design; Risk Assessment; Stents; Thiophenes; Ticlopidine; Treatment Outcome | 2009 |
Facts and controversies of aspirin and clopidogrel therapy.
Topics: Acute Coronary Syndrome; Aspirin; Atherosclerosis; Blood Platelets; Brain Ischemia; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Ticlopidine | 2009 |
Prasugrel STEMI subgroup analysis.
Topics: Aspirin; Clopidogrel; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Research Design; Thiophenes; Ticlopidine | 2009 |
Can we override clopidogrel resistance?
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Coronary Restenosis; Drug Resistance; Genotype; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Prasugrel Hydrochloride; Prodrugs; Radiography; Stents; Thiophenes; Ticlopidine | 2009 |
[Pharmazie in unserer Zeit 4/2009].
Topics: Aspirin; Atherosclerosis; Clopidogrel; Drug Resistance; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Ticlopidine | 2009 |
Test before you stop.
Topics: Adenosine; Algorithms; Aspirin; Clinical Trials as Topic; Clopidogrel; Humans; Perioperative Care; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Pyridines; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2009 |
Weighing benefits and risks--the FDA's review of prasugrel.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Causality; Clinical Trials as Topic; Combined Modality Therapy; Coronary Thrombosis; Drug Administration Schedule; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Neoplasms; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; United States; United States Food and Drug Administration | 2009 |
[Prasugrel or clopidogrel in patients with coronary intervention].
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Artery Bypass; Double-Blind Method; Endpoint Determination; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Thiophenes; Ticlopidine | 2009 |
Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Drug-Eluting Stents; Europe; Hemorrhage; Humans; Ischemic Attack, Transient; Myocardial Infarction; Neoplasms; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2; Recurrence; Stents; Stroke; Thiophenes; Ticlopidine; Treatment Outcome | 2009 |
P2Y12 inhibitors: thienopyridines and direct oral inhibitors.
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Atherosclerosis; Coronary Artery Bypass; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Postoperative Complications; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Stroke; Thiophenes; Ticagrelor | 2009 |
Trial watch. DAPT study.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Male; Multicenter Studies as Topic; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2010 |
Response to antiplatelet treatment: from genes to outcome.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Clopidogrel; Cytochrome P-450 CYP2C19; Humans; Pharmacogenetics; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Prasugrel Hydrochloride; Stents; Thiophenes; Ticlopidine | 2010 |
Clinical impact of enhanced inhibition of P2Y12-mediated platelet aggregation in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.
Topics: Adenosine; Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Electrocardiography; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2010 |
Antiplatelet and antithrombotic treatment after primary percutaneous coronary intervention: balancing safety and efficacy.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Administration Schedule; Fibrinolytic Agents; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Safety; Secondary Prevention; Thiophenes; Ticlopidine; Treatment Outcome; Warfarin | 2010 |
Resistance to anti-platelet agents.
Topics: Adenosine; Aspirin; Clopidogrel; Drug Resistance; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
[Multiple arterial thrombosis and resistance to conventional antiaggregation].
Topics: Aged; Angiography; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Resistance; Electrocardiography; Female; Femoral Artery; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombosis; Ticlopidine | 2011 |
Aspirin has little additional anti-platelet effect in healthy volunteers receiving prasugrel.
Topics: Adolescent; Adult; Aspirin; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Thromboxanes | 2011 |
Antiplatelet effects of aspirin vary with level of P2Y₁₂ receptor blockade supplied by either ticagrelor or prasugrel.
Topics: Adenosine; Aspirin; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor | 2011 |
Impact of dyspnea on medical utilization and affiliated costs in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Costs and Cost Analysis; Diagnostic Techniques and Procedures; Drug Therapy, Combination; Dyspnea; Emergency Service, Hospital; Female; Humans; Insurance Claim Review; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2011 |
Ticagrelor (Brilinta)--better than clopidogrel (Plavix)?
Topics: Adenosine; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Approval; Drug Interactions; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine; United States | 2011 |
A case of acute stent thrombosis during treatment with the thrombopoietin receptor agonist peptide--romiplostim.
Topics: Acute Disease; Aspirin; Chest Pain; Clopidogrel; Eptifibatide; Female; Humans; Middle Aged; Peptides; Piperazines; Platelet Aggregation Inhibitors; Platelet Count; Prasugrel Hydrochloride; Purpura, Thrombocytopenic, Idiopathic; Receptors, Thrombopoietin; Risk Factors; Stents; Thiophenes; Thrombosis; Ticlopidine; Ultrasonography, Interventional | 2012 |
Esophageal mucosal lesion with low-dose aspirin and prasugrel mimics malignancy: a case report.
Topics: Aspirin; Diagnosis, Differential; Drug-Eluting Stents; Esophageal Neoplasms; Esophagus; Humans; Intestinal Mucosa; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes | 2011 |
Cost-effectiveness of prasugrel in a US managed care population.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Cost Control; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Humans; Interviews as Topic; Male; Managed Care Programs; Middle Aged; Models, Economic; Outcome Assessment, Health Care; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; United States | 2012 |
Post percutaneous coronary intervention antiplatelet therapy: current perceptions, prospects and perplexity.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Coronary Restenosis; Drug Resistance; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans; Metals; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prosthesis Design; Risk Assessment; Risk Factors; Stents; Tetrazoles; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome | 2011 |
Rivaroxaban (Xarelto) for acute coronary syndrome.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Approval; Drug Therapy, Combination; Factor Xa Inhibitors; Humans; Morpholines; Pyridines; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; United States; United States Food and Drug Administration | 2011 |
New look at antiplatelet agent-related peptic ulcer: an update of prevention and treatment.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Interactions; Gastrointestinal Hemorrhage; Helicobacter Infections; Helicobacter pylori; Humans; Peptic Ulcer; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Thiophenes; Ticlopidine | 2012 |
Prasugrel inhibits platelet-leukocyte interaction and reduces inflammatory markers in a model of endotoxic shock in the mouse.
Topics: Animals; Anti-Inflammatory Agents; Aspirin; Biomarkers; Blood Platelets; Disease Models, Animal; Down-Regulation; Humans; Inflammation Mediators; Leukocytes; Macrophage-1 Antigen; Male; Mice; Mice, Inbred C57BL; Nitric Oxide; Piperazines; Platelet Adhesiveness; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Selenoprotein P; Shock, Septic; Thiophenes; Thromboxane B2; Tumor Necrosis Factor-alpha | 2012 |
The ancient drug salicylate directly activates AMP-activated protein kinase.
Topics: Amino Acid Substitution; AMP-Activated Protein Kinases; Animals; Aspirin; Binding Sites; Biphenyl Compounds; Carbohydrate Metabolism; Cell Line; Enzyme Activation; Enzyme Activators; HEK293 Cells; Humans; Lipid Metabolism; Liver; Mice; Mice, Knockout; Mutation; Oxygen Consumption; Phosphorylation; Pyrones; Rats; Salicylates; Thiophenes | 2012 |
CYP2C19 genotype-guided antiplatelet therapy in a patient with clopidogrel resistance.
Topics: Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug Resistance; Genotype; Humans; Male; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stents; Thiophenes; Ticlopidine; Treatment Outcome | 2012 |
Atrial fibrillation and acute myocardial infarction: antithrombotic therapy and outcomes.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Comorbidity; Drug Therapy, Combination; Female; Fibrinolytic Agents; Hemorrhage; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Patient Discharge; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Research Design; Risk Assessment; Stroke; Thiophenes; Ticlopidine; Treatment Outcome; Warfarin | 2012 |
[Removal of epidural catheter under dual antiplatelet therapy following acute coronary syndrome : scenario without special consideration to the current guidelines on epidural regional anesthesia].
Topics: Acute Coronary Syndrome; Analgesia, Epidural; Aspirin; Catheterization; Clopidogrel; Digestive System Surgical Procedures; Drug Interactions; Hemorrhage; Humans; Male; Middle Aged; Pain, Postoperative; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Risk; Thiophenes; Ticlopidine | 2012 |
Effects of rivaroxaban, acetylsalicylic acid and clopidogrel as monotherapy and in combination in a porcine model of stent thrombosis.
Topics: Animals; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Morpholines; Platelet Aggregation; Rivaroxaban; Stents; Swine; Swine, Miniature; Thiophenes; Thrombosis; Ticlopidine | 2012 |
Abciximab for distal thromboaspiration catheter-related embolization in ST-segment elevated myocardial infarction.
Topics: Abciximab; Antibodies, Monoclonal; Anticoagulants; Aspirin; Combined Modality Therapy; Coronary Angiography; Coronary Thrombosis; Coronary Vessels; Electrocardiography; Embolism; Enoxaparin; Female; Humans; Immunoglobulin Fab Fragments; Infusions, Parenteral; Injections, Intra-Arterial; Middle Aged; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Stents; Suction; Thiophenes; Thrombectomy | 2012 |
Safety of reloading prasugrel in addition to clopidogrel loading in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aspirin; Chi-Square Distribution; Clopidogrel; Endpoint Determination; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Statistics, Nonparametric; Thiophenes; Ticlopidine; Treatment Outcome | 2013 |
Circulating microRNAs as novel biomarkers for platelet activation.
Topics: Adult; Aspirin; Biomarkers; Blood Platelets; Blood Specimen Collection; Carotid Artery Diseases; Case-Control Studies; Clinical Trials as Topic; Confounding Factors, Epidemiologic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Monitoring; Drug Synergism; Drug Therapy, Combination; Gene Expression Profiling; Humans; Male; MicroRNAs; Piperazines; Plasma; Platelet Activation; Platelet Aggregation Inhibitors; Platelet-Rich Plasma; Prasugrel Hydrochloride; Real-Time Polymerase Chain Reaction; Serum; Thiophenes; Young Adult | 2013 |
Unclassified pleomorphic and spindle cell pulmonary neoplasm with brain metastases after prasugrel.
Topics: Aged; Aspirin; Brain Neoplasms; Carcinoma; Clinical Trials, Phase III as Topic; Clopidogrel; Colonic Neoplasms; Coronary Stenosis; Diabetes Mellitus, Type 1; Diabetic Cardiomyopathies; Drug Therapy, Combination; Drug-Eluting Stents; Fatal Outcome; Female; Humans; Lung Neoplasms; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Thiophenes; Ticlopidine; Time Factors | 2013 |
Triple antithrombotic therapy with prasugrel in the stented patient: concern for more bleeding.
Topics: Anticoagulants; Aspirin; Drug-Eluting Stents; Female; Humans; Male; Myocardial Ischemia; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes | 2013 |
Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Clopidogrel; Cohort Studies; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Myocardial Ischemia; Patient Selection; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Vitamin K | 2013 |
Influence of genetic polymorphisms on platelet function, response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease.
Topics: Adenosine; Aryl Hydrocarbon Hydroxylases; Aryldialkylphosphatase; Aspirin; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Humans; Pharmacogenetics; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Ticagrelor improves peripheral arterial function in patients with a previous acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Blood Pressure; Case-Control Studies; Clopidogrel; Endothelium, Vascular; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Peripheral Arterial Disease; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Preserved thrombin-inducible platelet activation in thienopyridine-treated patients.
Topics: Adenosine Diphosphate; Aged; Angioplasty; Aspirin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Female; Humans; Integrin beta3; Male; Middle Aged; P-Selectin; Peptide Fragments; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Membrane Glycoprotein IIb; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stents; Thiophenes; Thrombin; Ticlopidine | 2013 |
Cytochrome P450 2B6 and 2C9 genotype polymorphism--a possible cause of prasugrel low responsiveness.
Topics: Aryl Hydrocarbon Hydroxylases; Aspirin; Biomarkers, Pharmacological; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C9; Drug Resistance; Drug Therapy, Combination; Female; Gene Frequency; Genetic Association Studies; Genotype; Humans; Male; Middle Aged; Piperazines; Polymorphism, Genetic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine | 2013 |
Contra: "New oral anticoagulants should not be used as 1st choice for secondary stroke prevention in atrial fibrillation".
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Middle Aged; Morpholines; Patient Safety; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Warfarin | 2013 |
Pro: "The novel oral anticoagulants should be used as 1st choice for secondary prevention in patients with atrial fibrillation.".
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Diabetes Complications; Female; Hemorrhage; Humans; Hypertension; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Warfarin | 2013 |
Gastrointestinal adverse events after dual antiplatelet therapy: clopidogrel is safer than ticagrelor, but prasugrel data are lacking or inconclusive.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Chemical and Drug Induced Liver Injury; Clinical Trials, Phase III as Topic; Clopidogrel; Double-Blind Method; Female; Gastrointestinal Hemorrhage; Gastrointestinal Neoplasms; Humans; Kaplan-Meier Estimate; Male; Multicenter Studies as Topic; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Impact of aspirin dose on adenosine diphosphate-mediated platelet activities. Results of an in vitro pilot investigation.
Topics: Adenosine Diphosphate; Aged; Aspirin; Cell Adhesion Molecules; Coronary Artery Disease; Drug Dosage Calculations; Female; Humans; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Pilot Projects; Piperazines; Platelet Activation; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thiophenes | 2013 |
Critical illness-related corticosteroid insufficiency in cardiogenic shock.
Topics: Adrenal Insufficiency; Adrenergic alpha-Agonists; Adult; Anti-Inflammatory Agents; Antihypertensive Agents; Aspirin; Bisoprolol; Critical Illness; Epinephrine; Fibrinolytic Agents; Hirudins; Humans; Hydrocortisone; Male; Peptide Fragments; Piperazines; Prasugrel Hydrochloride; Ramipril; Recombinant Proteins; Shock, Cardiogenic; Thiophenes; Treatment Outcome | 2013 |
Cost-effectiveness of different strategies for stroke prevention in patients with atrial fibrillation in a health resource-limited setting.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; China; Clopidogrel; Cost-Benefit Analysis; Drug Therapy, Combination; Humans; Models, Economic; Morpholines; Platelet Aggregation Inhibitors; Quality-Adjusted Life Years; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Ticlopidine; Warfarin | 2014 |
Association of thrombin generation potential with platelet PAR-1 regulation and P-selectin expression in patients on dual antiplatelet therapy.
Topics: Adult; Aged; Aspirin; Biomarkers; Blood Platelets; Case-Control Studies; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; P-Selectin; Peptide Fragments; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prothrombin; Receptor, PAR-1; Thiophenes; Thrombin; Ticlopidine | 2014 |
Acute dysphagia after myocardial infarction: an unusual complication of anticoagulation therapy.
Topics: Anticoagulants; Aspirin; Cysts; Deglutition Disorders; Electrocardiography; Fibrinolytic Agents; Hematoma; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Premedication; Stents; Tenecteplase; Thiophenes; Thyroid Diseases; Thyroidectomy; Tissue Plasminogen Activator | 2014 |
Smoking status and the effects of antiplatelet drugs.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Smoking; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Comparative evaluation of direct thrombin and factor Xa inhibitors with antiplatelet agents under flow and static conditions: an in vitro flow chamber model.
Topics: Adenosine Triphosphate; Adult; Anticoagulants; Antithrombins; Aspirin; Benzimidazoles; beta-Alanine; Blood Platelets; Dabigatran; Dose-Response Relationship, Drug; Factor Xa; Factor Xa Inhibitors; Female; Fibrin; Humans; Lab-On-A-Chip Devices; Male; Microscopy, Confocal; Morpholines; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Rivaroxaban; Thiophenes; Thrombin; Thromboplastin; Thrombosis | 2014 |
Clopidogrel resistance in diabetic patient with acute myocardial infarction due to stent thrombosis.
Topics: Aged, 80 and over; Aspirin; Clopidogrel; Coronary Angiography; Diabetes Mellitus, Type 2; Drug Resistance; Electrocardiography; Heparin; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stents; Thiophenes; Thrombosis; Ticlopidine | 2014 |
Safer heart-attack prevention for seniors with revised drug regimen. Half the normal dose of prasugrel, a lifesaving medication, is just as effective as the larger dose, and reduces risk of serious side effects.
Topics: Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Secondary Prevention; Thiophenes; Ticlopidine | 2013 |
Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Drug Therapy, Combination; Enoxaparin; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Prospective Studies; Randomized Controlled Trials as Topic; Risk Assessment; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2014 |
Expert position paper on the management of antiplatelet therapy in patients undergoing coronary artery bypass graft surgery.
Topics: Adenosine; Aspirin; Blood Platelets; Clopidogrel; Consensus; Coronary Artery Bypass; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Postoperative Care; Prasugrel Hydrochloride; Preoperative Care; Purinergic P2Y Receptor Antagonists; Risk Assessment; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Triple antithrombotic therapy: risky but sometimes necessary.
Topics: Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Clopidogrel; Dabigatran; Drug Therapy, Combination; Humans; Morpholines; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Ticlopidine; Vitamin K | 2014 |
Fatal bleedings with prasugrel as part of triple antithrombotic therapy.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Arteriovenous Malformations; Aspirin; Drug Therapy, Combination; Fatal Outcome; Gastrointestinal Hemorrhage; Humans; Intracranial Hemorrhages; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stents; Thiophenes; Thrombosis; Warfarin | 2014 |
Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
Topics: Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Comparative Effectiveness Research; Cost-Benefit Analysis; Dabigatran; Factor Xa Inhibitors; Female; France; Humans; Male; Morpholines; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
Impact of the adjusted dosing regimen of prasugrel for Japanese patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Topics: Aspirin; Humans; Piperazines; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine | 2014 |
Peri-procedural interrupted oral anticoagulation for atrial fibrillation ablation: comparison of aspirin, warfarin, dabigatran, and rivaroxaban.
Topics: Administration, Oral; Aged; Algorithms; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Combined Modality Therapy; Dabigatran; Female; Heparin; Humans; Male; Middle Aged; Morpholines; Postoperative Complications; Radio Waves; Rivaroxaban; Thiophenes; Thromboembolism; Warfarin | 2014 |
[The clinical analysis of atrial fibrillation of 1 310 in patients in Urumqi of China].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibrillation; China; Comorbidity; Diabetes Mellitus; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Humans; Hypertension; Incidence; Inpatients; Male; Morpholines; Retrospective Studies; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2014 |
PRASFIT-ACS: important evidence against a "one-guideline-fits-all-races" approach to antiplatelet therapy.
Topics: Aspirin; Humans; Piperazines; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine | 2014 |
PRASFIT-ACS: important evidence against a "one-guideline-fits-all-races" approach to antiplatelet therapy.
Topics: Aspirin; Humans; Piperazines; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine | 2014 |
Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Cohort Studies; Coronary Artery Disease; Female; Graft Occlusion, Vascular; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Prospective Studies; Registries; Stents; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Dual antiplatelet therapy after drug-eluting stents--how long to treat?
Topics: Aspirin; Clopidogrel; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombosis; Ticlopidine | 2014 |
Long-term secondary prevention after high-risk stenting: a good drug for a bad stent.
Topics: Aspirin; Coronary Disease; Drug-Eluting Stents; Female; Humans; Male; Paclitaxel; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes | 2015 |
Antiplatelet therapy: risks and benefits of extended DAPT after stenting.
Topics: Aspirin; Cardiovascular Diseases; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thiophenes; Thrombosis; Ticlopidine | 2015 |
Prolonged dual antiplatelet therapy after drug-eluting stent reduces the risk of stent thrombosis and major cardiovascular events but increases the rate of bleeding.
Topics: Aspirin; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Thiophenes; Thrombosis; Ticlopidine | 2015 |
Investigation of possible prophylactic, renoprotective, and cardioprotective effects of thromboprophylactic drugs against ischemia-reperfusion injury.
Topics: Animals; Anticoagulants; Aryldialkylphosphatase; Aspirin; Cardiotonic Agents; Clopidogrel; Dipeptidases; Drug Evaluation, Preclinical; Enoxaparin; Femoral Artery; Heparin, Low-Molecular-Weight; Hindlimb; Kidney; Male; Malondialdehyde; Morpholines; Myocardium; Nitric Oxide; Oxidative Stress; Rats, Sprague-Dawley; Reperfusion Injury; Rivaroxaban; Thiophenes; Ticlopidine | 2015 |
Predictors of high on-aspirin platelet reactivity in high-risk vascular patients treated with single or dual antiplatelet therapy.
Topics: Adenosine; Aged; Aspirin; Cerebrovascular Disorders; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Fibrinogen; Humans; Male; Middle Aged; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Predictive Value of Tests; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Secondary Prevention; Thiophenes; Ticagrelor; Ticlopidine | 2015 |
Balancing the risks and benefits of dual platelet inhibition.
Topics: Adenosine; Aspirin; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine | 2015 |
ACP journal club. Dual antiplatelets for 30 mo after drug-eluting stents reduced stent thrombosis and CV and cerebrovascular events.
Topics: Aspirin; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Thiophenes; Thrombosis; Ticlopidine | 2015 |
Duration of dual antiplatelet therapy after drug-eluting stents.
Topics: Aspirin; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Thiophenes; Thrombosis; Ticlopidine | 2015 |
Duration of dual antiplatelet therapy after drug-eluting stents.
Topics: Aspirin; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Thiophenes; Thrombosis; Ticlopidine | 2015 |
Duration of dual antiplatelet therapy after drug-eluting stents.
Topics: Aspirin; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Thiophenes; Thrombosis; Ticlopidine | 2015 |
Duration of dual antiplatelet therapy after drug-eluting stents.
Topics: Aspirin; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Thiophenes; Thrombosis; Ticlopidine | 2015 |
Duration of dual antiplatelet therapy after drug-eluting stents.
Topics: Aspirin; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Thiophenes; Thrombosis; Ticlopidine | 2015 |
Duration of dual antiplatelet therapy after drug-eluting stents.
Topics: Aspirin; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Thiophenes; Thrombosis; Ticlopidine | 2015 |
Letter by Shah and Buch regarding article, "prasugrel plus aspirin beyond 12 months is associated with improved outcomes after TAXUS Liberté paclitaxel-eluting coronary stent placement".
Topics: Aspirin; Coronary Disease; Drug-Eluting Stents; Female; Humans; Male; Paclitaxel; Piperazines; Purinergic P2Y Receptor Antagonists; Thiophenes | 2015 |
Letter by Jeger and Pfisterer regarding article, "prasugrel plus aspirin beyond 12 months is associated with improved outcomes after TAXUS Liberté paclitaxel-eluting coronary stent placement".
Topics: Aspirin; Coronary Disease; Drug-Eluting Stents; Female; Humans; Male; Paclitaxel; Piperazines; Purinergic P2Y Receptor Antagonists; Thiophenes | 2015 |
Response to letters regarding article, "prasugrel plus aspirin beyond 12 months is associated with improved outcomes after TAXUS Liberté paclitaxel-eluting coronary stent placement".
Topics: Aspirin; Coronary Disease; Drug-Eluting Stents; Female; Humans; Male; Paclitaxel; Piperazines; Purinergic P2Y Receptor Antagonists; Thiophenes | 2015 |
Synthesis, Cyclooxygenase Inhibition, Anti-Inflammatory Evaluation, and Ulcerogenic Liability of New 1,3,5-Triarylpyrazoline Derivatives Possessing a Methanesulfonyl Pharmacophore.
Topics: Animals; Anti-Inflammatory Agents; Aspirin; Celecoxib; Cyclooxygenase Inhibitors; Isoenzymes; Pyrazoles; Rats; Sheep; Structure-Activity Relationship; Thiophenes; Ulcer | 2016 |
Aspirin Attenuates the Bioactivation of and Platelet Response to Vicagrel in Mice.
Topics: Activation, Metabolic; Animals; Aspirin; Blood Platelets; Carboxylesterase; Carboxylic Ester Hydrolases; Chromatography, Liquid; Drug Interactions; Male; Mice, Inbred C57BL; Phenylacetates; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Tandem Mass Spectrometry; Thiophenes | 2018 |
Vicagrel enhances aspirin-induced inhibition of both platelet aggregation and thrombus formation in rodents due to its decreased metabolic inactivation.
Topics: Animals; Aspirin; Blood Platelets; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Inactivation, Metabolic; Male; Mice, Inbred C57BL; Phenylacetates; Platelet Aggregation; Platelet Aggregation Inhibitors; Rats, Sprague-Dawley; Thiophenes; Thrombosis | 2019 |